Drug Database · Clinicians

Clarithromycin

Brands (97) Klaz, Clarifix, Clariget…Show all

Macrolide Antimicrobial (Cytochrome P450 3A4 Inhibitors; Cytochrome P450 3A Inhibitors; P-Glycoprotein Inhibitors) US FDA class
Antibacterial (macrolide); Antibaterial (macrolide) PH FDA category

CrCl <30: halve dose; no colchicineRx · Prescription drug161 PH productsPNF-listedPhilHealth GAMOT Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID d836ae7e-fdbf-4dcb-a90d-ede1dcbc3e67, version date September 16, 2026 (Clarithromycin · Sportpharm LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Clarithromycin tablets are a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults
  • Acute Maxillary Sinusitis
  • Community-Acquired Pneumonia
  • Pharyngitis/Tonsillitis
  • Uncomplicated Skin and Skin Structure Infections
  • Acute Otitis Media in Pediatric Patients
  • Treatment and Prophylaxis of Disseminated Mycobacterial Infections
  • Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Clarithromycin tablets are a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults (1.1) Acute Maxillary Sinusitis (1.2) Community-Acquired Pneumonia (1.3) Pharyngitis/Tonsillitis (1.4) Uncomplicated Skin and Skin Structure Infections (1.5) Acute Otitis Media in Pediatric Patients (1.6) Treatment and Prophylaxis of Disseminated Mycobacterial Infections (1.7) Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults (1.8) Limitations of Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.9) 1.1 Acute Bacterial Exacerbation of Chronic Bronchitis Clarithromycin tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae [see Indications and Usage (1.9)]. 1.2 Acute Maxillary Sinusitis Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae [see Indications and Usage (1.9)]. 1.3 Community-Acquired Pneumonia Clarithromycin tablets are indicated [see Indications and Usage (1.9)] for the treatment of mild to moderate infections caused by susceptible isolates due to: Haemophilus influenzae (in adults) Mycoplasma pneumoniae, Streptococcus pneumoniae, Chlamydophila pneumoniae (clarithromycin tablets [in adults and pediatric patients]) 1.4 Pharyngitis/Tonsillitis Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Streptococcus pyogenes as an alternative in individuals who cannot use first line therapy. 1.5 Uncomplicated Skin and Skin Structure Infections Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Acute Otitis Media Clarithromycin tablets are indicated in pediatric patients for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae [see Clinical Studies (14.2)]. 1.7 Treatment and Prophylaxis of Disseminated Mycobacterial Infections Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Mycobacterium avium or Mycobacterium intracellulare in patients with advanced HIV infection [see Clinical Studies (14.1)]. 1.8 Helicobacter pylori Infection and Duodenal Ulcer Disease Clarithromycin tablets are given in combination with other drugs in adults as described below to eradicate H. pylori.

The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence [see Clinical Studies (14.3)]. Clarithromycin tablets in combination with amoxicillin and PREVACID (lansoprazole) or PRILOSEC (omeprazole) Delayed-Release Capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori.

Clarithromycin tablets in combination with PRILOSEC (omeprazole) capsules are indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. Regimens which contain clarithromycin tablets as the single antibacterial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy.

Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. 1.9 Limitations of Use There is resistance to macrolides in certain bacterial infections caused by Streptococcus pneumoniae and Staphylococcus aureus. Susceptibility testing should be performed when clinically indicated. 1.10 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Contraindications

  • Hypersensitivity to clarithromycin or any macrolide
  • Cisapride, pimozide, ergot alkaloids, lurasidone, lomitapide, lovastatin, simvastatin
  • Colchicine in kidney or liver impairment
  • Previous cholestatic jaundice or hepatic dysfunction with clarithromycin
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

4 CONTRAINDICATIONS Hypersensitivity to clarithromycin or any macrolide drug (4.1) Cisapride and pimozide (4.2) History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin (4.3) Colchicine in renal or hepatic impairment (4.4) Lomitapide, lovastatin, and simvastatin (4.5) Ergot alkaloids (ergotamine or dihydroergotamine) (4.6) Lurasidone (4.7) 4.1 Hypersensitivity Clarithromycin tablets are contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibacterial drugs [see Warnings and Precautions (5.1)]. 4.2 Cisapride and Pimozide Concomitant administration of clarithromycin tablets with cisapride and pimozide is contraindicated [see Drug Interactions (7)]. There have been postmarketing reports of drug interactions when clarithromycin is co-administered with cisapride or pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes) most likely due to inhibition of metabolism of these drugs by clarithromycin tablets.

Fatalities have been reported. 4.3 Cholestatic Jaundice/Hepatic Dysfunction Clarithromycin tablets are contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin. 4.4 Colchicine Concomitant administration of clarithromycin tablets and colchicine is contraindicated in patients with renal or hepatic impairment. 4.5 Lomitapide, Lovastatin, and Simvastatin Concomitant administration of clarithromycin tablets with lomitapide is contraindicated due to potential for markedly increased transaminases [see Warnings and Precautions (5.4) and Drug Interactions (7)]. Concomitant administration of clarithromycin tablets with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin) is contraindicated, due to the increased risk of myopathy, including rhabdomyolysis [see Warnings and Precautions (5.4) and Drug Interactions (7)]. 4.6 Ergot Alkaloids Concomitant administration of clarithromycin and ergotamine or dihydroergotamine is contraindicated [see Drug Interactions (7)]. 4.7 Lurasidone Concomitant administration ofclarithromycin and lurasidone is contraindicated since it may result in an increase in lurasidone exposure and the potential for serious adverse reactions [see Drug Interactions (7)]. 4.8 Contraindications for Co-administered Drugs For information about contraindications of other drugs indicated in combination with clarithromycin tablets, refer to their full prescribing information (contraindications section).

Dosing: Adult

  • Mild to moderate infections (adults): 250 or 500 mg every 12 hours for 7 to 14 days
  • H. pylori (with amoxicillin and a PPI): 500 mg every 8 or 12 hours for 10 to 14 days
  • Mycobacterial infections: 500 mg every 12 hours
  • CrCl below 30 mL/min: Reduce by 50%
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label
  • Adults: Clarithromycin tablets 250 mg or 500 mg every 12 hours for 7 to 14 days (2.2)
  • H. pylori eradication (in combination with lansoprazole/amoxicillin, omeprazole/amoxicillin, or omeprazole): Clarithromycin tablets 500 mg every 8 or 12 hours for 10 to 14 days. See full prescribing information (FPI) for additional information. (2.3)
  • Pediatric Patients: Clarithromycin tablets 15 mg/kg/day divided every 12 hours for 10 days (2.4)
  • Mycobacterial Infections: Clarithromycin tablets 500 mg every 12 hours; clarithromycin tablets 7.5 mg/kg up to 500 mg every 12 hours in pediatric patients (2.5)
  • Reduce dose in moderate renal impairment with concomitant atazanavir or ritonavir-containing regimens and in severe renal impairment (2.6)
2.1 Important Administration Instructions

2.1 Important Administration Instructions Clarithromycin tablets may be given with or without food.

2.2 Adult Dosage

2.2 Adult Dosage The recommended dosages of clarithromycin tablets for the treatment of mild to moderate infections in adults are listed in Table 1. Table 1. Adult Dosage Guidelines Clarithromycin Tablets Infection Dosage (every 12 hours) Duration (days) Acute bacterial exacerbation of chronic bronchitis 250 to 500 mg a 7 b to 14 Acute maxillary sinusitis 500 mg 14 Community-acquired pneumonia 250 mg 7 d to 14 Pharyngitis/Tonsillitis 250 mg 10 Uncomplicated skin and skin structure infections 250 mg 7 to 14 Treatment and prophylaxis of disseminated Mycobacterium avium disease [see Dosage and Administration (2.5)] 500 mg e - H.pylori eradication to reduce the risk of duodenal ulcer recurrence with amoxicillin and omeprazole or lansoprazole [see Dosage and Administration (2.3)] 500 mg 10 to 14 H.pylori eradication to reduce the risk of duodenal ulcer recurrence with omeprazole [see Dosage and Administration (2.3)] 500 mg every 8 hours 14 a For M. catarrhalis and S. pneumoniae use 250 mg.

For H. influenzae and H. parainfluenzae, use 500 mg. b For H. parainfluenzae, the duration of therapy is 7 days. d For H. influenzae, the duration of therapy is 7 days. e Clarithromycin tablets therapy should continue if clinical response is observed. Clarithromycin tablets can be discontinued when the patient is considered at low risk of disseminated infection.

2.3 Combination Dosing Regimens for H

2.3 Combination Dosing Regimens for H. pylori Infection Triple therapy: Clarithromycin tablets/lansoprazole/amoxicillin The recommended adult dosage is 500 mg clarithromycin tablets, 30 mg lansoprazole, and 1 gram amoxicillin, all given every 12 hours for 10 or 14 days [see Indications and Usage (1.8) and Clinical Studies (14.3)]. Triple therapy: Clarithromycin tablets/omeprazole/amoxicillin The recommended adult dosage is 500 mg clarithromycin tablets, 20 mg omeprazole, and 1 gram amoxicillin; all given every 12 hours for 10 days.

In patients with an ulcer present at the time of initiation of therapy, an additional 18 days of omeprazole 20 mg once daily is recommended for ulcer healing and symptom relief [see Indications and Usage (1.8) and Clinical Studies (14.3)]. Dual therapy: Clarithromycin tablets/omeprazole The recommended adult dosage is 500 mg clarithromycin tablets given every 8 hours and 40 mg omeprazole given once every morning for 14 days.

An additional 14 days of omeprazole 20 mg once daily is recommended for ulcer healing and symptom relief [see Indications and Usage (1.8) and Clinical Studies (14.3)].

2.4 Pediatric Dosage

2.4 Pediatric Dosage The recommended daily dosage is 15 mg/kg/day divided every 12 hours for 10 days (up to the adult dose). Refer to dosage regimens for mycobacterial infections in pediatric patients for additional dosage information [see Dosage and Administration (2.5)].

2.5 Dosage Regimens for Mycobacterial Infections

2.5 Dosage Regimens for Mycobacterial Infections For the treatment of disseminated infection due to Mycobacterium avium complex (MAC), clarithromycin tablets are recommended as the primary agents. Clarithromycin tablets should be used in combination with other antimycobacterial drugs (e.g., ethambutol) that have shown in vitro activity against MAC or clinical benefit in MAC treatment [see Clinical Studies (14.1)].

Adult Patients For treatment and prophylaxis of mycobacterial infections in adults, the recommended dose of clarithromycin tablets is 500 mg every 12 hours. Pediatric Patients For treatment and prophylaxis of mycobacterial infections in pediatric patients, the recommended dose is 7.5 mg/kg every 12 hours up to 500 mg every 12 hours. [See Use in Specific Populations (8.4) and Clinical Studies (14.1)].

Clarithromycin tablets therapy should continue if clinical response is observed. Clarithromycin tablets can be discontinued when the patient is considered at low risk of disseminated infection.

2.6 Dosage Adjustment in Patients with Renal Impairment See

2.6 Dosage Adjustment in Patients with Renal Impairment See Table 2 for dosage adjustment in patients with moderate or severe renal impairment with or without concomitant atazanavir or ritonavir-containing regimens [see Drug Interactions (7)]. Table 2. Clarithromycin Tablets Dosage Adjustments in Patients with Renal Impairment Recommended Clarithromycin Tablets Dosage Reduction Patients with severe renal impairment (CL cr of <30 mL/min) Reduce the dosage of clarithromycin tablets by 50% Patients with moderate renal impairment (CL cr of 30 to 60 mL/min) taking concomitant atazanavir or ritonavir-containing regimens Reduce the dosage of clarithromycin tablets by 50% Patients with severe renal impairment (CL cr of <30 mL/min) taking concomitant atazanavir or ritonavir-containing regimens Reduce the dosage of clarithromycin tablets by 75%

2.7 Dosage Adjustment Due to Drug Interactions

2.7 Dosage Adjustment Due to Drug Interactions Decrease the dose of clarithromycin tablets by 50 % when co-administered with atazanavir [see Drug Interactions (7)]. Dosage adjustments for other drugs when co-administered with clarithromycin tablets may be recommended due to drug interactions [see Drug Interactions (7)].

Dosing: Altered kidney function

Clarithromycin is cleared by both the liver and the kidneys (20% to 30% unchanged in urine). The US label halves the dose when creatinine clearance (CrCl) is below 30 mL/min, and with atazanavir or ritonavir it halves the dose at CrCl 30–60 and cuts it by 75% below 30. Clarithromycin with colchicine is contraindicated in kidney impairment.

Kidney function measure: Label uses CrCl (mL/min); bands at 60 and 30.

Show full dosing details
CrCl ≥60 mL/min
No dose change (label).
CrCl 30–59 mL/min
No dose change, unless taking atazanavir or a ritonavir-containing regimen: then reduce by 50% (CrCl 30–60) (label).
CrCl 15–29 mL/min
CrCl below 30: reduce dose by 50%; with atazanavir or ritonavir-containing regimens, reduce by 75% (label).
CrCl <15 mL/min (not on dialysis)
CrCl below 30: reduce dose by 50%; with atazanavir or ritonavir-containing regimens, reduce by 75% (label).
Hemodialysis (intermittent)
Patients on dialysis fall in the label's CrCl below 30 group: reduce dose by 50%; clarithromycin is not appreciably removed by hemodialysis, so no supplement (label). Do not combine with colchicine.
Peritoneal dialysis
Patients on dialysis fall in the label's CrCl below 30 group: reduce dose by 50%; clarithromycin is not appreciably removed by peritoneal dialysis, so no supplement (label).
CRRT
Not in label; the cited CRRT review (Li 2020) gives no regimen for this drug. Specialist input.
  • Dialyzable? No: serum levels not expected to be appreciably affected by hemodialysis or peritoneal dialysis (label).
  • Monitoring CrCl for dose; QT interval and potassium/magnesium; liver tests; levels of CYP3A substrates (tacrolimus, cyclosporine, carbamazepine) and digoxin; blood pressure and kidney function with CYP3A-metabolized calcium channel blockers (label).
Children (kidney dosing)
Show full dosing details
eGFR ≥60
Usual pediatric dose (label).
eGFR 30–59
No pediatric kidney dosing in label (the CrCl table is not age-specific). Specialist input.
eGFR 15–29
No pediatric kidney dosing in label (the CrCl table is not age-specific). Specialist input.
eGFR <15 (not on dialysis)
No pediatric kidney dosing in label (the CrCl table is not age-specific). Specialist input.
Hemodialysis (intermittent)
No pediatric kidney dosing in label. Specialist input.
Peritoneal dialysis
No pediatric kidney dosing in label. Specialist input.
CRRT
No pediatric kidney dosing in label. Specialist input.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

US label text: Renal impairment US FDA label

2.6 Dosage Adjustment in Patients with Renal Impairment See Table 2 for dosage adjustment in patients with moderate or severe renal impairment with or without concomitant atazanavir or ritonavir-containing regimens [see Drug Interactions (7)]. Table 2. Clarithromycin Tablets Dosage Adjustments in Patients with Renal Impairment Recommended Clarithromycin Tablets Dosage Reduction Patients with severe renal impairment (CL cr of <30 mL/min) Reduce the dosage of clarithromycin tablets by 50% Patients with moderate renal impairment (CL cr of 30 to 60 mL/min) taking concomitant atazanavir or ritonavir-containing regimens Reduce the dosage of clarithromycin tablets by 50% Patients with severe renal impairment (CL cr of <30 mL/min) taking concomitant atazanavir or ritonavir-containing regimens Reduce the dosage of clarithromycin tablets by 75%

Renal Impairment The pharmacokinetics of clarithromycin was also altered in subjects with impaired renal function [see Use in Specific Populations (8.6) and Dosage and Administration (2.6)].

Dosing: Pediatric

Approved ages
6 months and older (label 8.4).
Usual dose
15 mg/kg/day divided every 12 hours for 10 days; mycobacterial infections 7.5 mg/kg (up to 500 mg) every 12 hours (label).
Maximum dose
500 mg per dose (label).

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed
Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of clarithromycin tablets have been established for the treatment of the following conditions or diseases in pediatric patients 6 months and older. Use in these indications is based on clinical trials in pediatric patients or adequate and well-controlled studies in adults with additional pharmacokinetic and safety data in pediatric patients: Pharyngitis/Tonsillitis Community-Acquired Pneumonia Acute maxillary sinusitis Acute otitis media [see Clinical Studies (14.2)] Uncomplicated skin and skin structure infections The safety and effectiveness of clarithromycin tablets have been established for the prevention of disseminated Mycobacterium avium complex (MAC) disease in pediatric patients 20 months and older with advanced HIV infection.

No studies of clarithromycin for MAC prophylaxis have been performed in pediatric populations and the doses recommended for prophylaxis are derived from MAC pediatric treatment studies. Safety and effectiveness of clarithromycin in pediatric patients under 6 months of age have not been established. The safety of clarithromycin has not been studied in MAC patients under the age of 20 months.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use In a steady-state study in which healthy elderly subjects (65 years to 81 years of age) were given 500 mg of clarithromycin every 12 hours, the maximum serum concentrations and area under the curves of clarithromycin and 14-OH clarithromycin were increased compared to those achieved in healthy young adults. These changes in pharmacokinetics parallel known age-related decreases in renal function.

In clinical trials, elderly patients did not have an increased incidence of adverse reactions when compared to younger patients. Consider dosage adjustment in elderly patients with severe renal impairment. Elderly patients may be more susceptible to development of torsades de pointes arrhythmias than younger patients [see Warnings and Precautions (5.3)].

Most reports of acute kidney injury with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem, nifedipine) involved elderly patients 65 years of age or older [see Warnings and Precautions (5.4)]. Especially in elderly patients, there have been reports of colchicine toxicity with concomitant use of clarithromycin and colchicine, some of which occurred in patients with renal insufficiency.

Deaths have been reported in some patients [see Contraindications (4.4) and Warnings and Precautions (5.4)].

Administration

2.1 Important Administration Instructions Clarithromycin tablets may be given with or without food.

US FDA label

Dosage forms

Philippines

  • Film-coated tablet: 250 mg, 500 mg
  • Granule for suspension: 125 mg/5 mL, 250 mg per 5 mL, 250 mg/5 mL
  • Powder for suspension: 125 mg/5 mL, 250 mg/5 mL
  • Granule for oral suspension: 125 mg/5 mL, 250 mg/5 mL
  • Powder for oral suspension: 125 mg/5 mL, 250 mg/5 mL
  • Tablet: 500 mg
  • ) powder for oral suspension: 50 mg/mL (250 mg/5 mL
  • Extended-release tablet: 500 mg
  • Dispersible tablet: 125 mg
  • Granule for oral injection: 250 mg/5 mL

and 4 more forms; see the products table.

Registered products in the Philippines

161 products registered with the Food and Drug Administration (FDA) Philippines list Clarithromycin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products161
Philippine FDA-registered products for Clarithromycin
Package insert
AcceclarClarithromycin
500 mg Film-Coated TabletAlu Blister Pack x 10's (Box of of 50's)
Rx
Nabiqasim Industries (Private) LimitedPakistan
Accesspoint International Trading Inc.
DRP-16715
Jun 25, 2030
AccethromClarithromycin
125 mg / 5 mL Granules for Oral Suspension
Rx
—
Importer: Accesspoint International Trading Inc.
DRP-5932
Feb 21, 2027
AccethromClarithromycin
250 mg per 5 mL Granules for SuspensionWhite HDPE Bottle with pilfer-proof, child-resistant bottle cap x 50 mL and 70 mL (Box of 1's)
Rx
Opal Laboratories (Pvt.) LimitedPakistan
Accesspoint International Trading Inc.
DRP-5924
Jan 5, 2030
AcroxynClarithromycin
500 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
TGP Pharma Inc.Trader: Euro-Health Care Exponents, Inc.
DRP-3613
Aug 7, 2029
AmbikacinClarithromycin
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s)
Rx
Brawn Laboratories LimitedIndia
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-4073-05
Oct 24, 2027
AmsoclarClarithromycin
125 mg/5 mL Powder for Oral Suspension (Oral Drops)Amber Glass Bottle x 25 mL with Dropper (Box of 1's)
Rx
Macter International LtdKarachi 75700 Pakistan
Amson PharmaceuticalsImporter: Sahar International Trading Inc
DRP-7682-01
Feb 23, 2031
Amsoclar-DSClarithromycin
250mg/5 mL Powder for Oral SuspensionAmber Glass Bottle x 60 mL (Box of 1's)
Rx
Macter International Ltd.Pakistan
Amson PharmaceuticalsImporter: Sahar International Trading, Inc
DRP-7684-01
Feb 17, 2031
Baclecin-500Clarithromycin
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s)
Rx
XL Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-1596
Feb 11, 2037
BiaxinClarithromycin
500 mg Lyophilized Powder for Injection I.V. InfusionType I Clear Glass Vial with grey bromobutyl rubber stopper and aluminum cap with flip-off seal (Box of 1's)
Rx
Anfarm Hellas S.A.Greece
Ambicare Pharmaceuticals Inc.
DRP-9182
Sep 30, 2030
Bruclar-500Clarithromycin
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s and 50’s)
Rx
Brawn Laboratories LimitedIndia
Ambica International Corporation
DRP-4073
Oct 24, 2027
ClabetClarithromycin
500 mg Film-Coated TabletBlister pack x 10’s (Box of 50’s)
Rx
Umedica Laboratories Pvt. Ltd.India
Better Option Pharmaceuticals, Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-625-02
Jun 23, 2031
ClacureClarithromycin
500 mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 50’s)
Rx
Umedica Laboratories Pvt. Ltd.India
Suhitas Pharmaceuticals Inc.
DRP-8585
Dec 18, 2029
ClafaxClarithromycin
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 50 's)
Rx
Medicraft Pharmaceutical (Pvt.) Ltd.Pakistan
Importer: Geo Pak International Trading Corp.
DR-XY40674
Feb 22, 2027
ClamisynClarithromycin
500 mg Film-Coated TabletBlister pack x 10’s (Box of 50’s)
Rx
Umedica Laboratories Pvt. Ltd.India
Starpharm, Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-625-04
Aug 19, 2031
ClarbactClarithromycin
500mg Tablet
Rx
Ipca Laboratories Limited
—
DRP-3772
Nov 19, 2026
ClaribaxClarithromycin
500 mg Film-Coated TabletBlister Pack 10's (Box of 50's)
Rx
J. M. Tolmann Laboratories Inc.Philippines
ALTOMED PHARMACEUTICALS, INC.Trader: Foramen Products Corporation
DRP-2774
Sep 18, 2028
ClaribidClarithromycin
500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Eadriex Pharmaceuticals, Phils., Inc.
DRP-7477
Nov 13, 2028
ClaridClarithromycin
500 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's Box of 100's
Rx
Lloyd Laboratories, Inc.Philippines
Nutramedica Inc.Trader: Euro-Health Care Exponents, Inc.
DRP-3613-02
Aug 7, 2029
Clarie DS 125Clarithromycin
125 mg/5 mL Powder for SuspensionHDPE Bottle x 50 mL (Box of 1's)
Rx
Ind-Swift Laboratories LimitedIndia
Genace Pharma DistributorImporter: Ambica International Corporation
DRP-2967
Jun 28, 2032
Clarie DS 250Clarithromycin
250 mg/5 mL Powder for SuspensionHDPE Bottle x 15 mL; 50 mL (Box of 1's)
Rx
Ind-Swift LimitedIndia
Ambica International Corporation
DRP-3651
Dec 16, 2027
ClarifixClarithromycin
125 mg/5mL Granules for Suspension60 mL HDPE White colored Bottle with pilfer proof child resistant bottle cap
Rx
Medisure Laboratories Pakistan (Pvt.) LimitedPakistan
Ellebasy Medicale TradingImporter: Accesspoint International Trading Inc.
DRP-5050-02
Jul 9, 2028
ClarifixClarithromycin
250 mg/5 mL Granules for SuspensionWhite HDPE Bottle x 50 mL and 70 mL (Box of 1's)
Rx
Medisure Laboratories Pakistan (Pvt.) Ltd.Pakistan
Ellebasy Medicale TradingImporter: Accesspoint International Trading Inc.
DRP-4825-02
Oct 16, 2028
ClarifixClarithromycin
500 mg Film-Coated TabletAlu/ Clear PVC Blister Pack x 10's (Box of 20's)
Rx
Medisure Laboratories Pakistan (Pvt.) LimitedPakistan
ELLEBASY Medicale TradingImporter: Accesspoint International Trading Inc.
DRP-5301-02
Aug 8, 2028
ClarigetClarithromycin
125 mg/5 mL Granules for SuspensionHDPE Bottle x 25 mL, 50 mL, and 70 mL (Box of 1's)
Rx
Getz Pharma (Pvt) Ltd.Pakistan
Getz Pharma (Phils.), Inc.
DR-XY31313
Jul 18, 2030
ClarigetClarithromycin
250 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's)
Rx
Getz Pharma Pvt. Ltd.Pakistan
Getz Pharma Phils., Inc.
DR-XY27861
Sep 4, 2030
ClarigetClarithromycin
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's)
Rx
Getz Pharma Pvt. Ltd.Pakistan
Getz Pharma Phils., Inc.
DR-XY27862
Sep 4, 2030
Clariget ODClarithromycin
500 mg Extended-Release TabletAlu/Alu Blister Packs x 5's (Box of f 5's)
Rx
Getz Pharma (Pvt.) Ltd.Pakistan
Getz Pharma (Phils.), Inc.
DR-XY37281
Aug 15, 2030
ClariglobClarithromycin
50 mg/mL (250 mg/5 mL) Powder for Oral Suspension (Raspberry Flavor)White HDPE Bottle Sealed with White PP Cap and PP Measuring Cup x 30 mL and 60 mL (Box of 1's)
Rx
Globela Pharma Private LimitedIndia
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-14634
Nov 8, 2028
Clarihex 250Clarithromycin
250 mg/5 mL Powder for Suspension70 mL HDPE bottle with measuring cup (Box of 1's)
Rx
Kwality Pharmaceuticals Ltd.India
Pharma-Surrey International, Inc
DRP-17506
Jan 19, 2031
ClarimacClarithromycin
125 mg/ 5 mL Powder for SuspensionAmber Glass Bottle x 60 mL with measuring cap (Box of 1's)
Rx
Macter International Ltd.Pakistan
Sahar International Trading Inc.
DRP-7683
Feb 23, 2031
ClarimacClarithromycin
125 mg/5 mL Powder for Suspension (Oral Drops)Amber Glass Bottle x 25 mL with Dropper (Box of 1's)
Rx
Macter International Ltd.Pakistan
Sahar International Trading Inc.Importer: Sahar International Trading Inc
DRP-7682
Feb 23, 2031
Clarimac DSClarithromycin
250 mg/5 mL Powder for Oral SuspensionAmber Glass Bottle x 60 mL (Box of 1's)
Rx
Macter International LtdPakistan
Sahar International Trading Inc
DRP-7684
Feb 17, 2031
ClarimidClarithromycin
125 mg/5 mL Granules for Suspension75 mL capacity translucent and round HDPE plastic bottle x 50 mL with white Polypropylene tamper proof cap and 20 mL capacity measuring cup (Box of 1's)
Rx
Interphil Laboratories, Inc.Philippines
—
DRP-2404
Apr 24, 2031
ClarimidClarithromycin
250 mg Film-Coated TabletAluminum Foil Strip x 4's (Box of 100's)
Rx
Interphil Laboratories, Inc.Philippines
—
DRP-2330
Aug 10, 2027
ClarimidClarithromycin
500 mg Film-Coated TabletAluminum Foil Strip x 4's (Box of 100's)
Rx
Interphil Laboratories, Inc.Philippines
—
DRP-2331
Aug 10, 2027
ClarinovaClarithromycin
500 mg Lyophilized Powder for Solution for Intravenous Infusion15 mL-capacity USP Type I Clear and Colorless Tubular Glass Vial Stoppered with Grey Bromobutyl Double-slotted Rubber Stopper along with baby Blue Aluminum Seal (Box of 1's)
Rx
Immacule Lifesciences Private LimitedIndia
Medinova Pharmaceutical, Inc.
DRP-8895
Sep 30, 2030
ClarionClarithromycin
125 mg/ 5 mL Granules for Suspension60 mL HDPE White Bottle with pilfer proof child resistant bottle cap
Rx
Medisure Laboratories Pakistan (Pvt.) LimitedPakistan
AEON FARMA TRADING INC.Importer: Accesspoint International Trading Inc.
DRP-5050-01
Jul 9, 2028
ClarionClarithromycin
250 mg / 5 mL Granules for SuspensionWhite HDPE Bottle x 50 mL and 70 mL (Box of 1's)
Rx
Medisure Laboratories Pakistan (Pvt.) LimitedPakistan
AEON FARMA TRADING INC.Importer: Accesspoint International Trading Inc.
DRP-4825-01
Oct 16, 2028
ClaripakClarithromycin
125 mg/ 5 mL Granules for Suspension60 mL HDPE White Bottle with pilfer proof child resistant bottle cap
Rx
Medisure Laboratories Pakistan (Pvt.) LimitedPakistan
GEO PAK INTERNATIONAL TRADING CORP.Importer: Accesspoint International Trading Inc.
DRP-5050-03
Jul 9, 2028
ClaripakClarithromycin
250 mg / 5 mL Granules for SuspensionWhite HDPE Bottle x 50 mL (Box of 1's); White HDPE Bottle x 70 mL (Box of 1's)
Rx
Medisure Laboratories Pakistan (Pvt.) LimitedPakistan
GEO PAK INTERNATIONAL TRADING CORP.Importer: Accesspoint International Trading Inc.
DRP-4825-03
Oct 16, 2028
ClaripakClarithromycin
500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 20's)
Rx
Medisure Laboratories Pakistan (Pvt.) LimitedPakistan
GEO PAK INTERNATIONAL TRADING CORP.Importer: Accesspoint International Trading Inc.
DRP-5301-03
Aug 8, 2028
ClariqClarithromycin
125mg/5mL Powder for Oral SuspensionHDPE Bottle x 50 mL, 60 mL and 70 mL (Box of 1's)
Rx
Zhejiang Zhongtong Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.
DRP-17201
Oct 20, 2030
ClariqClarithromycin
250mg/5mL Powder for Oral SuspensionHDPE Bottle x 50 mL, 60 mL and 70 mL (Box of 1’s)
Rx
Zhejiang Zhongtong Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.Trader: N/A
DRP-17171
Oct 20, 2030
Clarisaph-125Clarithromycin
125mg/5mL Granules For Oral SuspensionAmber Bottle x 60 mL and 120 mL with white aluminum cap (Box of 1's)
Rx
Bueno Salud Care (India) Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-14104
Jun 22, 2028
Clarisaph-500Clarithromycin
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Genom Biotech Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-13809
Mar 30, 2031
ClarisaveClarithromycin
125 mg / 5 mL Granules for Oral SuspensionHDPE White Colored Bottle with Pilfer Proof Child Resistant Cap x 60 mL (Box of 1's)
Rx
Opal Laboratories (Pvt.) LimitedPakistan
Savelink Pharma And Trading Co.Importer: Accesspoint International Trading Inc.
DRP-5932-03
Feb 21, 2027
ClarisaveClarithromycin
250 mg/ 5 mL Granules for SuspensionWhite HDPE bottle with pilfer-proof, child-resistant bottle cap x 70 mL (Box of 1's)
Rx
Opal Laboratories (Pvt.) LimitedPakistan
Savelink Pharma And Trading Co.Importer: Accesspoint International Trading Inc.
DRP-5924-03
Jan 5, 2030
Clariset-125Clarithromycin
125 mg / 5 mL Granules for Oral SuspensionHDPE White Colored Bottle with Pilfer Proof Child Resistant Cap x 60 mL (Box of 1's)
Rx
Opal Laboratories (Pvt.) LimitedPakistan
Eliset Pharmaceutical, Inc.Importer: Accesspoint International Trading Inc.
DRP-5932-2
Feb 21, 2027
Clariset-250Clarithromycin
250 mg per 5 mL Granules for SuspensionWhite HDPE Bottle with pilfer-proof, child-resistant bottle cap x 50 mL and 70 mL (Box of 1's)
Rx
Opal Laboratories (Pvt.) LimitedPakistan
Eliset Pharmaceutical, Inc.Importer: Accesspoint International Trading Inc.
DRP-5924-02
Jan 4, 2030
Clarithro-NatrapharmClarithromycin
125mg/5mL Granules for Oral SuspensionHigh Density Polyethylene (HDPE) Bottle w/Syringe x 50mL Box of 1's
Rx
Sandoz S.R.L.Romania
Natrapharm, Inc.Importer: Sandoz Philippines Corporation
DRP-2053-01
May 11, 2029
Clarithro-NatrapharmClarithromycin
250 mg/ 5 mL Granules for Oral SuspensionHigh Density Polyethylene (HDPE) Bottle with Syringe x 70 mL (Box of 1's)
Rx
Sandoz S.R.L.Romania
Natrapharm, Inc.Importer: Sandoz Philippines Corporation
DRP-3038-01
May 11, 2029
Clarithro-NatrapharmClarithromycin
500 mg Film-coated tabletAluminum Foil Strip x 4's (Box of 28's)
Rx
Interphil Laboratories, Inc.Philippines
Natrapharm, Inc.
DRP-2331-04
Aug 10, 2027
ClarithrocidClarithromycin
250 mg Film-Coated TabletAluminum Foil Strip x 6's (Box of 30's)
Rx
EL Laboratories, Inc.Philippines
Trader: The Cathay Drug Co., Inc.
DR-XY45157
Mar 11, 2031
ClarithrocidClarithromycin
250 mg/5 mL Granules for SuspensionOpaque White HDPE Plastic Bottle x 25 mL, 35 mL, 50 mL and 70 mL (Box of 1's)
Rx
EL Laboratories, Inc.Philippines
Trader: The Cathay Drug Company, Inc.
DRP-3634
Jan 2, 2027
ClarithrocidClarithromycin
500 mg Film-Coated TabletAluminum Foil Strip x 6's (Box of 30's)
Rx
EL Laboratories, Inc.Philippines
Trader: The Cathay Drug Co., Inc.
DR-XY45156
Mar 11, 2032
ClarithromaxClarithromycin
500 mg Film-Coated TabletAlu-Clear PVDC Blister Pack x 10's Box of 100's
Rx
Lloyd Laboratories, Inc.Philippines
Basic Pharmaceutical CorporationTrader: Euro-Health Care Exponents, Inc.
DRP-3613-03
Aug 7, 2029
ClarithromedClarithromycin
125mg/5mL Granules for Suspension (Tutti Frutti Flavor)Boston Round Amber Bottle (35 mL in 60 mL) Box of 1's; Boston Round Amber Bottle (50 mL in 60 mL) Box of 1's; Boston Round Amber Bottle (70 mL in 120 mL) Box of 1's
Rx
Drugmaker's Laboratories, Inc.Philippines
—
DRP-714
Dec 21, 2031
ClarithromedClarithromycin
500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Drugmaker's Laboratories, Inc.Philippines
—
DRP-6789
Sep 5, 2028
ClaritoneClarithromycin
50 mg/mL (250 mg/5 mL) Powder for Oral Suspension (Raspberry Flavor)White HDPE Bottle Sealed with White PP Cap and PP Measuring Cup x 30 mL and 60 mL (Box of 1's)
Rx
Globela Pharma Private LimitedIndia
PhilRx Pharma Inc.Importer: AMB HK Enterprises, Inc.
DRP-14634-01
Nov 8, 2028
ClaritrolClarithromycin
500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-12514
Aug 25, 2027
Clariva-500Clarithromycin
500 mg TabletAlu/PVC Blister Pack x 7's (Box of 14's); Alu/PVC Blister Pack x 7's (Box of 140's)
Rx
Oman Pharmaceutical Products Co., LLCOman
MG Prime Pharmaceutical, Inc.Importer: Atlantic Pharmaceuticals, Inc.
DRP-7506
Aug 25, 2030
ClariwellClarithromycin
125 mg/5 mL Powder For SuspensionHDPE Bottle x 30 mL and 50 mL (Box of 1’s)
Rx
Yashica Pharmaceuticals Pvt. Ltd.India
Wellchem Pharmaceutical Products
DRP-5918
Jan 5, 2030
ClariwellClarithromycin
250 mg/5 mL Powder For SuspensionHDPE Bottle x 30 mL and 70 mL (Box of 1’s)
Rx
Yashica Pharmaceuticals Pvt. Ltd.India
Wellchem Pharmaceutical Products
DRP-6060
Mar 16, 2030
ClariwinClarithromycin
250 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 10's and 30's)
Rx
Micro Labs LimitedIndia
Brown & Burk Phils., Inc.
DRP-1374
May 18, 2028
Clariwin DTClarithromycin
125 mg Dispersible TabletAlu/Alu Strip Foil x 10's (Box of 30's)
Rx
Micro Labs LimitedIndia
Brown & Burk Philippines Inc.
DR-XY42544
Sep 6, 2028
ClartrixelClarithromycin
500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 5 blister packs x 10 tablets)
Rx
Umedica Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambicare Pharmaceuticals, Inc.
DRP-13752
Apr 5, 2028
ClarylClarithromycin
500 mg Film-Coated TabletBlister pack x 10’s (Box of 50’s)
Rx
Umedica Laboratories Pvt. Ltd.India
Suhitas Pharmaceuticals Inc.
DRP-625
Aug 15, 2031
ClarynClarithromycin
500 mg Film-Coated TabletAlu/PVDC Clear Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Medhaus Pharma, Incorporated
DR-XY37720
Mar 31, 2030
ClasynerClarithromycin
500 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 7's)
Rx
Synmedic LaboratoriesIndia
Ambica International Corporation.Importer: Ambica International Corporation
DRP-14706
Dec 1, 2028
CleocinClarithromycin
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's and 100's)
Rx
Medico Remedies LimitedIndia
All-Bio Pharma Inc.Importer: Medethix, Inc.
DRP-4550
Jul 26, 2028
Clistanex ForteClarithromycin
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
Flamingo Pharmaceuticals Ltd.India
Hexagon Pharmaceuticals
DRP-2351
Jun 30, 2029
Clitrosaph-A125Clarithromycin
125mg/5mL Granules for Oral SuspensionPET Round Amber Bottle Sealed with ROPP Aluminum Cap x 60mL and 120mL (Box of 1's)
Rx
Avantika Medex Private LimitedIndia
Nelpa Lifesciences, Inc.
DRP-17282
Nov 6, 2030
Clitrosaph-A250Clarithromycin
250mg/5mL Granules for Oral SuspensionPET Round Amber Bottle Sealed with ROPP Aluminum Cap x 60mL and 120mL (Box of 1's)
Rx
Avantika Medex Private LimitedIndia
Nelpa Lifesciences, Inc.
DRP-17275
Nov 5, 2030
Clitrosaph-I125Clarithromycin
125 mg/ 5 mL Granules For Oral SuspensionPET Round Amber Glass Bottle Sealed with ROPP Cap x 60 mL and 120 mL (Box of 1's)
Rx
Innova Captab Ltd.India
Nelpa Lifesciences, Inc.
DRP-18641
Aug 11, 2031
Clitrosaph-I250Clarithromycin
250 mg/5 mL Granules For Oral SuspensionPET Round Amber Glass Bottle Sealed with ROPP Cap x 60 mL and 120 mL (Box of 1's)
Rx
Innova Captab Ltd.India
Nelpa Lifesciences, Inc.
DRP-18640
Aug 11, 2031
CymicinClarithromycin
125 mg/ 5 mL Powder for Suspension (Oral Drops)Amber Glass Bottle x 25 mL with dropper (Box of 1's)
Rx
Macter International LtdKarachi 75700 Pakistan
Ellebasy Medicale TradingImporter: Sahar International Trading Inc
DRP-7682-02
Feb 23, 2031
CymicinClarithromycin
125 mg/5 mL Powder for Suspension (Oral Drops)Amber Glass Bottle x 60 mL with Measuring Cup (Box of 1's)
Rx
Macter International Ltd.Pakistan
Ellebasy Mediclae TradingImporter: Sahar International Trading, Inc.
DRP-7683-01
Feb 23, 2031
CymicinClarithromycin
250 mg/5mL Powder for Oral SuspensionAmber Glass Bottle x 60 mL (Box of 1's)
Rx
Macter International Ltd.Pakistan
Ellebasy Medicale TradingImporter: Sahar International Trading Inc.
DRP-7684-02
Feb 17, 2031
ExeclarClarithromycin
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s and 50’s)
Rx
Brawn Laboratories LimitedIndia
Excelcare, Inc.Importer: Ambica International Corporation
DRP-4073-04
Oct 24, 2027
FarmclarClarithromycin
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s Box of 10’s
Rx
Brawn Laboratories LimitedIndia
Diafarm Inc.Importer: Ambica International Corporation
DRP-4073-01
Oct 24, 2027
Fevaxid DS 250Clarithromycin
250 mg / 5 mL Powder for SuspensionHDPE Bottle x 50 mL (Box of 1's)
Rx
Ind-Swift LimitedIndia
Guimhealth Pharmaceutical Distributor and DrugstoreImporter: Ambica International Corporation
DRP-3651-03
Dec 16, 2027
Fexavid DS 125Clarithromycin
125 mg/5 mL Powder for SuspensionHDPE Bottle x 50 mL (Box of 1's)
Rx
Ind-Swift Laboratories LimitedIndia
Guimhealth Pharmaceutical Distributor and DrugstoreImporter: Ambica International Corporation
DRP-2967-01
Jun 28, 2032
KlaitreneClarithromycin
125 mg/5 mL Powder for SuspensionHDPE Bottle x 50 mL (Box of 1's)
Rx
Ind-Swift LimitedIndia
Aisec Farma CorporationImporter: Ambica International Corporation
DRP-2967-03
Jun 28, 2027
KlaitreneClarithromycin
250 mg/5 mL Powder for SuspensionHDPE Bottle x 15 mL (Box of 1's); HDPE Bottle x 50 mL (Box of 1's)
Rx
Ind-Swift LimitedIndia
Aisec Farma CorporationImporter: Ambica International Corporation
DRP-3651-04
Dec 16, 2027
KlarcynClarithromycin
500 mg Film-Coated TabletPVC-Alu Blister Pack x 10's (Box of 50's)
Rx
Swiss Parenterals Pvt Ltd.India
Endure Medical, Inc.
DR-XY42461
Aug 29, 2028
KlarexClarithromycin
125 mg/5 mL Granules for Suspension60 mL HDPE white colored bottle with pilfer proof child resistant bottle cap
Rx
Medisure Laboratories Pakistan (Pvt.) LimitedPakistan
Rexmed Pharmaceutical SalesImporter: Accesspoint International Trading Inc.
DRP-5050-04
Jul 9, 2028
KlarexClarithromycin
250mg/5mL Granules for SuspensionWhite HDPE Bottle x 50ml and 70 mL Box of 1's
Rx
Medisure Laboratories Pakistan (Pvt.) LtdPakistan
Rexmed Pharmaceutical SalesImporter: Accesspoint International Trading Inc.
DRP-4825-04
Oct 16, 2028
KlarexClarithromycin
500 mg Film-Coated TabletAlu Clear PVC Blister Pack x 10's (Box of 50's)
Rx
Medisure Laboratories Pakistan (Pvt.) LimitedPakistan
Rexmed Pharmaceutical SalesImporter: Accesspoint International Trading Inc.
DRP-5301-04
Aug 8, 2028
Klari-KidClarithromycin
125 mg/5 mL Powder for Oral SuspensionHDPE Bottle 50 mL, 60 mL, and 70 mL (Box of 1’s)
Rx
Zhejiang Zhongtong Pharmaceutical Co., Ltd.China
PhilRx Pharma, Inc.Importer: AMB HK Enterprises, Inc.
DRP-17201-01
Oct 20, 2030
Klari-KidClarithromycin
250 mg/5 mL Powder for Oral SuspensionHDPE Bottle x 60 mL (Box of 1's)
Rx
Zhejiang Zhongtong Pharmaceutical Co., Ltd.China
PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc.
DRP-17171-01
Oct 20, 2030
KlaricidClarithromycin
125 mg/5 mL Granules for SuspensionHDPE Plastic Bottle x 25 mL (Box of 1's); HDPE Plastic Bottle x 50 mL (Box of 1's); HDPE Plastic Bottle x 70 mL (Box of 1's)
Rx
PT. Abbott IndonesiaIndonesia
Abbott Laboratories
DRP-1916
Jan 30, 2028
KlaricidClarithromycin
250 mg/5 mL Granules for SuspensionHDPE Bottle x 70 mL, 50 mL and 25 mL (Box of 1's)
Rx
PT. Abbott IndonesiaIndonesia
Abbott Laboratories
DRP-2199
Sep 8, 2029
Klaricid ODClarithromycin
500 mg Modified-Release TabletAlu/PVC/PVDC Blister Pack x 10 Tablets (Box of 30's); Alu/PVC/PVDC Blister Pack x 5 Tablets (Box of 5's)
Rx
AbbVie S.r.l.Italy
Importer: Abbott Laboratories
DRP-1290
Feb 15, 2031
KlaridClarithromycin
500 mg TabletAlu/PVC Blister Pack x 7's (Box of 14's)
Rx
LBS Laboratory Limited PartnershipThailand
Phil Pharmawealth, Inc.
DR-XY30532
Feb 10, 2029
KlariferClarithromycin
125 mg / 5 mL Granules for Oral SuspensionHDPE White Colored Bottle with Pilfer Proof Child Resistant Cap x 60 mL (Box of 1's)
Rx
Opal Laboratories (Pvt.) LimitedPakistan
Ferjan Healthlink Philippines, Inc.Importer: Accesspoint International Trading Inc.
DRP-5932-04
Feb 21, 2027
Klarifer-250Clarithromycin
250 mg per 5 mL Granules for SuspensionWhite HDPE Bottle with pilfer-proof, child-resistant bottle cap x 70 mL (Box of 1's)
Rx
Opal Laboratories (Pvt.) LimitedPakistan
Ferjan Philippines Inc.Importer: Accesspoint International Trading Inc.
DRP-5924-04
Jan 5, 2030
KlarilabClarithromycin
500 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Medico Remedies LimitedIndia
Labmate Pharma Inc.Importer: I.E. Medica, Inc.
DRP-4542-01
Jul 26, 2028
KlarimedClarithromycin
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Flamingo Pharmaceuticals Ltd.India
TRUMED PHARMACEUTICALSImporter: HEXAGON PHARMACEUTICALS
DRP-2351-02
Jun 30, 2029
KlarithixClarithromycin
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's); Alu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 10's (Box of 100's)
Rx
Medico Remedies LimitedIndia
Meedpharma Medical Supplies & Equipment DistributorImporter: I.E. Medica, Inc.
DRP-4542
Jul 26, 2028
KlarithroClarithromycin
250mg Film-Coated TabletsAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Fredun Pharmaceuticals LimitedIndia
Amb Hk Enterprises Inc.Importer: AMB HK Enterprises Inc.
DRP-14519
Sep 25, 2028
KlarithroClarithromycin
500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Baroque Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-15412
Jul 5, 2029
KlarithroClarithromycin
500mg Film-Coated TabletsAlu/PVC Blister Pack x 10's (Box 5 100's)
Rx
Fredun Pharmaceuticals LimitedIndia
Amb Hk Enterprises Inc.Importer: AMB HK Enterprises Inc.
DRP-14518
Sep 28, 2028
KlarmynClarithromycin
125 mg /5 mL Granules for Oral SuspensionHigh Density Polyethylene (HDPE) Bottle w/ Syringe x 50 mL (Box of 1's)
Rx
Sandoz S.R.L.Romania
Importer: Sandoz Philippines Corporation
DRP-2053
May 11, 2029
KlarmynClarithromycin
250 mg / 5 mL Granules for Oral SuspensionHigh Density Polyethylene (HDPE) Bottle with Syringe x 70 mL (Box of 1's)
Rx
Sandoz S.R.L.Romania
Importer: Sandoz Philippines Corporation
DRP-3038
May 11, 2029
Klarux 125Clarithromycin
125 mg / 5 mL Granules for Oral SuspensionHDPE White Colored Bottle with Pilfer Proof Child Resistant Cap x 60 mL (Box of 1's)
Rx
Opal Laboratories (Pvt.) LimitedPakistan
Medvybe Pharmaceutical TradingImporter: Accesspoint International Trading Inc.
DRP-5932-05
Feb 21, 2027
KlaruX 250Clarithromycin
250 mg per 5 mL Granules for SuspensionWhite HDPE Bottle with pilfer-proof, child-resistant bottle cap 70 mL (Box of 1's)
Rx
Opal Laboratories (Pvt.) LimitedPakistan
Medvybe Pharmaceutical TradingImporter: Accesspoint International Trading Inc.
DRP-5924-05
Jan 5, 2030
KlarythClarithromycin
250 mg/5 mL Granules for SuspensionOpaque White HDPE Plastic Bottle x 35 mL and 70 mL (Box of 1's)
Rx
EL Laboratories, Inc.Philippines
The Cathay YSS Distributors Co., Inc.Trader: The Cathay Drug Company, Inc.
DRP-3634-01
Jan 2, 2027
KlaryzClarithromycin
125 mg/ 5 mL Granules for Suspension (Tutti Frutti Flavor)Boston Round Amber Bottle x 35 mL (Box of 1's); Boston Round Amber Bottle x 50 mL (Box of 1's); Boston Round Amber Bottle x 70 mL (Box of 1's)
Rx
Drugmaker's Laboratories, Inc.Philippines
Terramedic, Inc.
DRP-714-01
Dec 21, 2031
KlaryzClarithromycin
500 mg Film-Coated TabletBlister Pack x 10's (Box of 30's)
Rx
Drugmaker's Laboratories, Inc.Laguna
Trader: Terramedic, Inc.
DR-XY40331
Nov 22, 2031
KlazClarithromycin
125 mg/5 mL Granules for SuspensionPlastic Bottle x 35 mL and 70 mL (Box of 1's)
Rx
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, Inc.
DR-XY27632
May 24, 2027
KlazClarithromycin
250 mg Film - Coated TabletAlu/ Clear PVC/ PVDC Blister pack x 10's Box of 50's
Rx
Amherst Laboratories, Inc.Philippines
UNILAB, Inc.
DRP-1534
Oct 24, 2027
KlazClarithromycin
250 mg/5 mL Granules For Oral Injection35 mL (net content) in 50 mL-capacity opaque white HDPE bottle with opaque white LDPE flip-top cap (box of 1 bottle) 70 mL (net content) in 100 mL-capacity opaque white HDPE bottle with opaque white LDPE flip-top cap (box of 1 bottle)
Rx
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, Inc.
DR-XY35736
Apr 27, 2027
KlazClarithromycin
500 mg Film-coated TabletBlister Pack x 10's (Box of 50's)
Rx
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, Inc.
DRP-1062
Jul 16, 2027
Klaz ODClarithromycin
500 mg Extended-Release TabletBlister Pack x 7's (Box of 70's)
Rx
Ind-Swift LimitedIndia
UNILAB, Inc.
DRP-904
Apr 18, 2031
KodacinClarithromycin
125 mg / 5 mL Granules for Oral SuspensionHDPE White Colored Bottle with Pilfer Proof Child Resistant Cap x 60 mL (Box of 1's)
Rx
Opal Laboratories (Pvt.) LimitedPakistan
Kodapharm Med Corp.Importer: Accesspoint International Trading Inc.
DRP-5932-01
Feb 21, 2027
KodacinClarithromycin
250 mg per 5 mL Granules for SuspensionWhite HDPE Bottle with pilfer-proof, child-resistant bottle cap x 50 mL and 70 mL (Box of 1's)
Rx
Opal Laboratories (Pvt.) LimitedPakistan
Kodapharm Med Corp.Importer: Accesspoint International Trading Inc.
DRP-5924-01
Jan 5, 2030
KracidClarithromycin
500mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 100's)
Rx
Fredun Pharmaceuticals Ltd.India
Khriz Pharma Trading Inc.
DRP-11773
Apr 27, 2027
KXDClarithromycin
125 mg/5 mL Granules for SuspensionOpaque White Plastic Bottle x 50 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Prosel Pharmaceuticals & Distributors, Inc.
DR-XY35019
Oct 10, 2028
KXDClarithromycin
500 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 24's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Prosel Pharmaceuticals & Distributors, Inc.
DR-XY34999
Oct 3, 2028
LifemycinClarithromycin
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's in a Box
Rx
Brawn Laboratories LimitedIndia
Pharmalife DistributionImporter: Ambica International Corporation
DRP-4073-02
Oct 24, 2027
MaclarClarithromycin
500 mg Film-Coated TabletClear PVC/PE/PVDC-Alu Blister Pack x 4's (Box of 28's)
Rx
Glenmark Pharmaceuticals Ltd.India
Glenmark Philippines, Inc.
DRP-6885
Mar 12, 2037
MacritinClarithromycin
500 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Medirich Pharma Distribution Corp.Trader: Euro-Health Care Exponents, Inc.
DRP-3613-01
Aug 7, 2029
MacromycinClarithromycin
500 mg Film-Coated TabletAlu/PVDC Clear Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Totalcare Pharma Inc.
DR-XY41729
Feb 28, 2028
MacromycinClarithromycin
500 mg Film-Coated TabletAlu/PVDC Clear Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, IncPhilippines
Trader: Totalcare Pharma Inc.
DRP-15627
Feb 28, 2028
MaxulidClarithromycin
125 mg/5 mL Granules for Oral Suspension78 mL USP Type I Amber Bottle (60 mL net content)
Rx
Emil Pharmaceutical Industries Pvt. Ltd.India
IBERICA VERHEILEN PHARMACEUTICALS GROUP CORP.Importer: VERHEILEN IBERICA HEALTH CARE COMPANY INC.Trader: Verheilen Pharmaceuticals GmbH
DRP-3421
Dec 22, 2030
MyzinClarithromycin
500 mg Film-Coated TabletAlu/PVDC Clear Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Aldril Pharmaceuticals, Inc.
DR-XY41721
Feb 21, 2028
MyzinClarithromycin
500 mg Film-Coated TabletAlu / PVDC Clear Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Aldril Pharmaceuticals, Inc.
DRP-16077
Feb 21, 2028
NoneClarithromycin
125 mg / 5 mL Granules for Suspension60 mL HDPE white colored bottle with pilfer proof child resistant bottle cap Not Applicable
Rx
Medisure Laboratories Pakistan (Pvt.) LimitedPakistan
Reta DrugImporter: Accesspoint International Trading Inc.
DRP-5050-06
Jul 9, 2028
NoneClarithromycin
125 mg /5 mL Granules for SuspensionAmber Glass Bottle x 70 mL and 120 mL (Box of 1's)
Rx
Pascual Laboratories, Inc.Philippines
Pharex Health Corporation
DR-XY40348
Dec 1, 2028
NoneClarithromycin
125 mg/5 mL Powder for SuspensionHDPE Bottle x 50 mL (Box of 1's)
Rx
Ind-Swift LimitedIndia
Watsons Personal Care Stores (Philippines), Inc.Importer: Ambica International Corporation
DRP-2967-02
Jun 28, 2027
NoneClarithromycin
125 mg/5 mL Powder for SuspensionHDPE Bottle x 50 mL (Box of 1's)
Rx
Ind-Swift LimitedIndia
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-2967-04
Jun 28, 2027
NoneClarithromycin
250 mg / 5 mL Granules for SuspensionWhite HDPE Bottle x 70 mL (Box of 1's)
Rx
Medisure Laboratories Pakistan (Pvt.) LimitedPakistan
Reta DrugImporter: Accesspoint International Trading Inc.
DRP-4825-06
Oct 16, 2028
NoneClarithromycin
250 mg / 5 mL Powder for SuspensionHDPE Bottle x 50 mL (Box of 1's)
Rx
Ind-Swift LimitedIndia
Ritemed Phils., Inc.Importer: Ambica International Corporation
DRP-3651-02
Dec 16, 2027
NoneClarithromycin
250 mg Film Coated TabletAluminum foil strip x 4's (Box of 100's)
Rx
Interphil Laboratories Inc.Philippines
Neodrug, Inc
DRP-2330-01
Aug 10, 2027
NoneClarithromycin
250 mg/5 mL Powder for SuspensionHDPE Bottle x 15 mL and 50mL (Box of 1's)
Rx
Ind-Swift LimitedIndia
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-3651-05
Dec 16, 2027
NoneClarithromycin
250 mg/5 mL Powder for SuspensionHDPE Bottle x 15 mL ; 50 mL (Box of 1’s)
Rx
Ind-Swift LimitedIndia
Altomed Pharmaceuticals, Inc.Importer: Ambica International Corporation
DRP-3651-06
Dec 16, 2027
NoneClarithromycin
250 mg/5 mL Powder for SuspensionHDPE Bottle x 15 mL; 50 mL (Box of 1’s)
Rx
Ind-Swift Laboratories LimitedIndia
PharmaVital Corp.Importer: Ambica International Corporation
DRP-3651-07
Dec 16, 2027
NoneClarithromycin
500 mg Film Coated TabletAluminum Foil Strip x 4's (Box of 100's)
Rx
Interphil Laboratories Inc.Philippines
Neodrug, Inc.
DRP-2331-02
Aug 10, 2027
NoneClarithromycin
500 mg Film Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
Flamingo Pharmaceuticals Ltd.India
Qualifirst Health Inc.Importer: Hexagon Pharmaceuticals
DRP-2351-04
Jun 30, 2029
NoneClarithromycin
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 50's)
Rx
Micro Labs LimitedIndia
Ritemed Phils., Inc.
DRP-1260
May 18, 2028
NoneClarithromycin
500 mg Film-Coated TabletAlu-Alu Blister Pack x 10’s (Box of 10’s)
Rx
XL Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-1596-01
May 6, 2037
NoneClarithromycin
500 mg Film-Coated TabletAluminum Foil Strip x 4's (Box of 100's)
Rx
Interphil Laboratories Inc.Philippines
Rose Pharmacy, Incorporated
DRP-2331-03
Aug 10, 2027
NoneClarithromycin
500 mg Film-Coated TabletAluminum Foil Strip x 4's (Box of 100's)
Rx
Interphil Laboratories, Inc.Philippines
South Star Drug
DRP-2331-05
Aug 10, 2027
NoneClarithromycin
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 10's
Rx
Brawn Laboratories LimitedIndia
ATC Healthcare International Corp.Importer: Ambica International Corporation
DRP-4073-03
Oct 24, 2027
NoneClarithromycin
500 mg Film-Coated tabletAlu/Alu Blister Pack x 10's (Box of 10's); Alu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 10's (Box of 100's)
Rx
Medico Remedies LimitedIndia
Medethix, Inc.Importer: I.E. Medica, Inc.
DRP-4542-02
Jul 26, 2028
NoneClarithromycin
500 mg Film-Coated TabletAlu Clear PVC Blister Pack x 10's (Box of 50's)
Rx
Medisure LaboratoriesPakistan
Reta DrugImporter: Accesspoint International Trading Inc.
DRP-5301-05
Aug 8, 2028
NoneClarithromycin
500 mg Film-Coated TabletAlu/PVC Blister pack x 10's (Box of 30's)
Rx
Drugmaker's Laboratories, Inc.Philippines
TGP Pharma Inc.
DRP-6789-01
Sep 5, 2028
NoneClarithromycin
500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Watsons Personal Care Stores (Philippines), Inc.Trader: Eadriex Pharmaceuticals, Phils., Inc.
DRP-7477-01
Nov 13, 2028
NoneClarithromycin
500 mg TabletBlister pack x 10's (Box of 50's)
Rx
Amherst Laboratories, Inc.Philippines
Ritemed Phils., Inc.
DRP-1062-02
Jul 16, 2027
NumedClarithromycin
500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
East African (India) OverseasIndia
Airlife International Trading Corporation
DRP-17826
Mar 17, 2031
PediaklarClarithromycin
125 mg/5 mL Granules for SuspensionAmber Bottle x 50 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Medlink Pharma Phils., Inc.
DR-XY42434
Aug 29, 2028
PrimycinClarithromycin
250 mg/5 mL Powder for SuspensionHDPE Bottle x 50 mL (Box of 1's)
Rx
Ind-Swift LimitedIndia
Primera Pharma CorporationImporter: Ambica International Corporation
DRP-3651-01
Dec 16, 2027
RahmacinClarithromycin
125 mg/5 mL Granules for Suspension60 mL HDPE white colored bottle with pilfer proof child resistant bottle cap
Rx
Medisure Laboratories Pakistan (Pvt.) LimitedPakistan
Accesspoint International Trading Inc.
DRP-5050
Jul 9, 2028
RahmacinClarithromycin
250 mg / 5 mL Granules for SuspensionWhite HDPE Bottle x 50 mL (Box of 1's); White HDPE Bottle x 70 mL (Box of 1's)
Rx
Medisure Laboratories Pakistan (Pvt.) LimitedPakistan
Accesspoint International Trading Inc.
DRP-4825
Oct 16, 2028
RahmacinClarithromycin
500 mg Film-Coated TabletAlu Clear PVC Blister Pack x 10's Box of 50's
Rx
Medisure Laboratories Pakistan (Pvt.) LimitedPakistan
Accesspoint International Trading Inc.
DRP-5301
Aug 8, 2028
RixoClarithromycin
125 mg/ 5 mL Granules for Suspension60 mL HDPE white colored bottle with pilfer proof child resistant bottle cap
Rx
Medisure Laboratories Pakistan (Pvt.) LimitedPakistan
Ellebasy Medicale Group Inc.Importer: Accesspoint International Trading Inc.
DRP-5050-05
Jul 9, 2028
RixoClarithromycin
250 mg / 5 mL Granules for SuspensionWhite HDPE Bottle x 70 mL (Box of 1's)
Rx
Medisure Laboratories Pakistan (Pvt.) LimitedPakistan
Ellebasy Medicale Group Inc.Importer: Accesspoint International Trading Inc.
DRP-4825-05
Oct 16, 2028
SefdyClarithromycin
500 mg Lyophilized Powder for Injection for I.V. InfusionType I Clear Glass Vial with Grey Bromobutyl Rubber Stopper and Aluminum Cap with Flip-Off Seal (Box of 1's)
Rx
Anfarm Hellas S.A.Greece
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambicare Pharmaceuticals Inc.
DRP-9182-01
Feb 24, 2031
SydencinClarithromycin
500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Sydenham Laboratories, Inc.Philippines
Sydenham Pharmaceuticals, Inc.
DRP-1718
Sep 14, 2027
UnbrandedClarithromycin
125 mg/5 mL Powder for SuspensionHDPE Bottle x 50 mL (Box of 1's)
Rx
Ind-Swift Laboratories LimitedIndia
PharmaVital Corp.Importer: Ambica International Corporation
DRP-2967-05
Jun 28, 2032
UnbrandedClarithromycin
125mg/5mL Granules for SuspensionBoston Round Amber Bottle x 50mL (Box of 1's)
Rx
Drugmaker's Laboratories Inc.Philippines
TGP Pharma Inc.
DRP-714-03
Dec 21, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Clarithromycin tablets USP are available as: 250 mg: light yellow colored, oval shaped, biconvex film-coated tablets, with ‘D’ debossed on one side and ‘62’ on the other side. 500 mg: light yellow colored, oval shaped, biconvex film-coated tablets, with ‘D’ debossed on one side and ‘63’ on the other side. Tablets: 250 mg and 500 mg (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Severe Acute Hypersensitivity Reactions: Discontinue clarithromycin if occurs (5.1)
  • QT Prolongation: Avoid clarithromycin in patients with known QT prolongation or receiving drugs known to prolong the QT interval, ventricular arrhythmia (torsades de pointes), hypokalemia /hypomagnesemia, significant bradycardia, or taking Class IA or III antiarrhythmics (5.2)
  • Hepatotoxicity: Discontinue if signs and symptoms of hepatitis occur (5.3)
  • Serious adverse reactions can occur due to drug interactions of clarithromycin with colchicine, some lipid-lowering agents, some calcium channel blockers, and other drugs (5.4)
  • Risk of all-cause mortality one year or more after the end of treatment in patients with coronary artery disease. Balance this potential risk with the treatment benefits when prescribing clarithromycin in these patients (5.5)
  • Clostridium difficile associated diarrhea (CDAD): Evaluate if diarrhea occurs (5.6)
  • Embryo-Fetal Toxicity: Based on animal findings, clarithromycin is not recommended for use in pregnant women except in clinical circumstances where no alternative therapy is appropriate (5.7)
  • Exacerbation of myasthenia gravis has been reported in patients receiving clarithromycin therapy (5.8)
5.1 Severe Acute Hypersensitivity Reactions

5.1 Severe Acute Hypersensitivity Reactions In the event of severe acute hypersensitivity reactions, such as anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS), Henoch-Schonlein purpura, and acute generalized exanthematous pustulosis, discontinue clarithromycin therapy immediately and institute appropriate treatment.

5.2 QT Prolongation

5.2 QT Prolongation Clarithromycin has been associated with prolongation of the QT interval and infrequent cases of arrhythmia. Cases of torsades de pointes have been spontaneously reported during postmarketing surveillance in patients receiving clarithromycin. Fatalities have been reported. Avoid clarithromycin in the following patients: patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes patients receiving drugs known to prolong the QT interval [see also Contraindications (4.2)] patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia and in patients receiving Class IA (e.g., quinidine, procainamide, disopyramide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents.

Elderly patients may be more susceptible to drug-associated effects on the QT interval [see Use in Specific Populations (8.5)].

5.3 Hepatotoxicity

5.3 Hepatotoxicity Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported with clarithromycin. This hepatic dysfunction may be severe and is usually reversible. In some instances, hepatic failure with fatal outcome has been reported and generally has been associated with serious underlying diseases and/or concomitant medications.

Symptoms of hepatitis can include anorexia, jaundice, dark urine, pruritus, or tender abdomen. Discontinue clarithromycin immediately if signs and symptoms of hepatitis occur.

5.4 Serious Adverse Reactions Due to Concomitant Use with Other Drugs

5.4 Serious Adverse Reactions Due to Concomitant Use with Other Drugs Drugs metabolized by CYP3A4: Serious adverse reactions have been reported in patients taking clarithromycin concomitantly with CYP3A4 substrates. These include colchicine toxicity with colchicine; markedly increased transaminases with lomitapide; rhabdomyolysis with simvastatin, lovastatin, and atorvastatin; hypoglycemia and cardiac arrhythmias (e.g., torsades de pointes) with disopyramide; and hypotension and acute kidney injury with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem, nifedipine).

Most reports of acute kidney injury with calcium channel blockers metabolized by CYP3A4 involved elderly patients 65 years of age or older. Use clarithromycin with caution when administered concurrently with medications that induce the cytochrome CYP3A4 enzyme. The use of clarithromycin with lomitapide, simvastatin, lovastatin, ergotamine, or dihydroergotamine is contraindicated [see Contraindications (4.5, 4.6) and Drug Interactions (7)].

Colchicine: Life-threatening and fatal drug interactions have been reported in patients treated with clarithromycin and colchicine. Clarithromycin is a strong CYP3A4 inhibitor and this interaction may occur while using both drugs at their recommended doses. If co-administration of clarithromycin and colchicine is necessary in patients with normal renal and hepatic function, reduce the dose of colchicine.

Monitor patients for clinical symptoms of colchicine toxicity. Concomitant administration of clarithromycin and colchicine is contraindicated in patients with renal or hepatic impairment [see Contraindications (4.4) and Drug Interactions (7)]. Lomitapide: Concomitant use of clarithromycin with lomitapide is contraindicated [see Contraindications (4.5)].

Lomitapide is metabolized by CYP3A4, and concomitant treatment with clarithromycin increases the plasma concentration of lomitapide, which increases the risk of elevation in transaminases [see Drug Interactions (7)]. If treatment with clarithromycin cannot be avoided, therapy with lomitapide must be suspended during the course of treatment.

HMG-CoA Reductase Inhibitors (statins): Concomitant use of clarithromycin with lovastatin or simvastatin is contraindicated [see Contraindications (4.5)] as these statins are extensively metabolized by CYP3A4, and concomitant treatment with clarithromycin increases their plasma concentration, which increases the risk of myopathy, including rhabdomyolysis. Cases of rhabdomyolysis have been reported in patients taking clarithromycin concomitantly with these statins.

If treatment with clarithromycin cannot be avoided, therapy with lovastatin or simvastatin must be suspended during the course of treatment. Exercise caution when prescribing clarithromycin with atorvastatin or pravastatin. In situations where the concomitant use of clarithromycin with atorvastatin or pravastatin cannot be avoided, atorvastatin dose should not exceed 20 mg daily and pravastatin dose should not exceed 40 mg daily.

Use of a statin that is not dependent on CYP3A metabolism (e.g., fluvastatin) can be considered. It is recommended to prescribe the lowest registered dose if concomitant use cannot be avoided. Oral Hypoglycemic Agents/Insulin: The concomitant use of clarithromycin and oral hypoglycemic agents and/or insulin can result in significant hypoglycemia.

With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of CYP3A enzyme by clarithromycin may be involved and could cause hypoglycemia when used concomitantly. Careful monitoring of glucose is recommended [see Drug Interactions (7)]. Quetiapine: Use quetiapine and clarithromycin concomitantly with caution.

Co-administration could result in increased quetiapine exposure and quetiapine related toxicities such as somnolence, orthostatic hypotension, altered state of consciousness, neuroleptic malignant syndrome, and QT prolongation. Refer to quetiapine prescribing information for recommendations on dose reduction if co-administered with CYP3A4 inhibitors such as clarithromycin [see Drug Interactions (7)].

Oral Anticoagulants: There is a risk of serious hemorrhage and significant elevations in INR and prothrombin time when clarithromycin is co-administered with warfarin. Monitor INR and prothrombin times frequently while patients are receiving clarithromycin and oral anticoagulants concurrently [see Drug Interactions (7)].

Benzodiazepines: Increased sedation and prolongation of sedation have been reported with concomitant administration of clarithromycin and triazolobenzodiazepines, such as triazolam and midazolam [see Drug Interactions (7)].

5.5 All-Cause Mortality in Patients With Coronary Artery Disease 1 to 10 Years After

5.5 All-Cause Mortality in Patients With Coronary Artery Disease 1 to 10 Years After Clarithromycin Exposure In one clinical trial evaluating treatment with clarithromycin on outcomes in patients with coronary artery disease, an increase in risk of all-cause mortality one year or more after the end of treatment was observed in patients randomized to receive clarithromycin. 1 Clarithromycin for treatment of coronary artery disease is not an approved indication. The cause of the increased risk has not been established.

Other epidemiologic studies evaluating this risk have shown variable results [see Adverse Reactions (6.1)]. Consider balancing this potential risk with the treatment benefits when prescribing clarithromycin in patients who have suspected or confirmed coronary artery disease.

5.6 Clostridium difficile Associated Diarrhea

5.6 Clostridium difficile Associated Diarrhea Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including clarithromycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use.

Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

5.7 Embryo-Fetal Toxicity

5.7 Embryo-Fetal Toxicity Based on findings from animal studies, clarithromycin is not recommended for use in pregnant women except in clinical circumstances where no alternative therapy is appropriate. If clarithromycin is used during pregnancy, or if pregnancy occurs while the patient is taking this drug, the patient should be apprised of the potential hazard to the fetus.

Clarithromycin demonstrated adverse effects on pregnancy outcome and/or embryo fetal development, including fetal malformations, in pregnant animals administered oral clarithromycin [see Use in Specific Populations (8.1)].

5.8 Exacerbation of Myasthenia Gravis

5.8 Exacerbation of Myasthenia Gravis Exacerbation of symptoms of myasthenia gravis and new onset of symptoms of myasthenic syndrome has been reported in patients receiving clarithromycin therapy.

5.9 Development of Drug Resistant Bacteria

5.9 Development of Drug Resistant Bacteria Prescribing clarithromycin in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Drug interactions

Drug or classSeverityEffectWhat to do
ColchicineAvoidFatal colchicine toxicity (label).Contraindicated in kidney or liver impairment; reduce colchicine dose otherwise.
Lovastatin, simvastatin, lomitapideAvoidRhabdomyolysis; raised transaminases (label).Contraindicated.
CYP3A-metabolized calcium channel blockers (amlodipine, nifedipine, diltiazem, verapamil)Adjust or monitorHypotension and acute kidney injury, mainly in older adults (label).Monitor blood pressure and creatinine.
Tacrolimus, cyclosporine, other narrow-margin CYP3A substratesAdjust or monitorHigher levels (label).Monitor levels; adjust dose.
DigoxinAdjust or monitorHigher digoxin levels (P-gp inhibition) (label).Monitor digoxin level.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed
Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS Co-administration of clarithromycin is known to inhibit CYP3A, and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug. Clarithromycin should be used with caution in patients receiving treatment with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g., carbamazepine) and/or the substrate is extensively metabolized by this enzyme.

Adjust dosage when appropriate and monitor serum concentrations of drugs primarily metabolized by CYP3A closely in patients concurrently receiving clarithromycin. Table 8: Clinically Significant Drug Interactions with Clarithromycin Drugs That Are Affected By Clarithromycin Drug(s) with Pharmacokinetics Affected by Clarithromycin Recommendation Comments Antiarrhythmics: Disopyramide Quinidine Dofetilide Amiodarone Sotalol Procainamide Digoxin Not Recommended Use With Caution Disopyramide, Quinidine: There have been postmarketing reports of torsades de pointes occurring with concurrent use of clarithromycin and quinidine or disopyramide.

Electrocardiograms should be monitored for QTc prolongation during coadministration of clarithromycin with these drugs [see Warnings and Precautions (5.2)]. Serum concentrations of these medications should also be monitored. There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with disopyramide and quinidine.

There have been postmarketing reports of hypoglycemia with the concomitant administration of clarithromycin and disopyramide. Therefore, blood glucose levels should be monitored during concomitant administration of clarithromycin and disopyramide. Digoxin: Digoxin is a substrate for P-glycoprotein (Pgp) and clarithromycin is known to inhibit Pgp.

When clarithromycin and digoxin are co-administered, inhibition of Pgp by clarithromycin may lead to increased exposure of digoxin. Elevated digoxin serum concentrations in patients receiving clarithromycin and digoxin concomitantly have been reported in postmarketing surveillance. Some patients have shown clinical signs consistent with digoxin toxicity, including potentially fatal arrhythmias.

Monitoring of serum digoxin concentrations should be considered, especially for patients with digoxin concentrations in the upper therapeutic range. Oral Anticoagulants: Warfarin Use With Caution Oral anticoagulants: Spontaneous reports in the postmarketing period suggest that concomitant administration of clarithromycin and oral anticoagulants may potentiate the effects of the oral anticoagulants.

Prothrombin times should be carefully monitored while patients are receiving clarithromycin and oral anticoagulants simultaneously [see Warnings and Precautions (5.4)]. Antiepileptics: Carbamazepine Use With Caution Carbamazepine: Concomitant administration of single doses of clarithromycin and carbamazepine has been shown to result in increased plasma concentrations of carbamazepine.

Blood level monitoring of carbamazepine may be considered. Increased serum concentrations of carbamazepine were observed in clinical trials with clarithromycin. There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with carbamazepine. Antifungals: Itraconazole Fluconazole Use With Caution No Dose Adjustment Itraconazole: Both clarithromycin and itraconazole are substrates and inhibitors of CYP3A, potentially leading to a bi-directional drug interaction when administered concomitantly (see also Itraconazole under “Drugs That Affect Clarithromycin” in the table below).

Clarithromycin may increase the plasma concentrations of itraconazole. Patients taking itraconazole and clarithromycin concomitantly should be monitored closely for signs or symptoms of increased or prolonged adverse reactions. Fluconazole: [see Pharmacokinetics (12.3)] Anti-Gout Agents: Colchicine (in patients with renal or hepatic impairment) Colchicine (in patients with normal renal and hepatic function) Contraindicated Use With Caution Colchicine: Colchicine is a substrate for both CYP3A and the efflux transporter, P-glycoprotein (Pgp).

Clarithromycin and other macrolides are known to inhibit CYP3A and Pgp. The dose of colchicine should be reduced when co-administered with clarithromycin in patients with normal renal and hepatic function [see Contraindications (4.4) and Warnings and Precautions (5.4)]. Antipsychotics: Pimozide Quetiapine Lurasidone Contraindicated Pimozide: [See Contraindications (4.2)] Quetiapine: Quetiapine is a substrate for CYP3A4, which is inhibited by clarithromycin.

Co-administration with clarithromycin could result in increased quetiapine exposure and possible quetiapine related toxicities. There have been postmarketing reports of somnolence, orthostatic hypotension, altered state of consciousness, neuroleptic malignant syndrome, and QT prolongation during concomitant administration.

Refer to quetiapine prescribing information for recommendations on dose reduction if co-administered with CYP3A4 inhibitors such as clarithromycin. Lurasidone: [See Contraindications (4.7)] Antispasmodics: Tolterodine (patients deficient in CYP2D6 activity) Use With Caution Tolterodine: The primary route of metabolism for tolterodine is via.

CYP2D6. However, in a subset of the population devoid of CYP2D6, the identified pathway of metabolism is via. CYP3A. In this population subset, inhibition of CYP3A results in significantly higher serum concentrations of tolterodine. Tolterodine 1 mg twice daily is recommended in patients deficient in CYP2D6 activity (poor metabolizers) when co-administered with clarithromycin.

Antivirals: Atazanavir Saquinavir (in patients with decreased renal function) Ritonavir Etravirine Maraviroc Boceprevir (in patients with normal renal function) Didanosine Zidovudine Use With Caution No Dose Adjustment Atazanavir: Both clarithromycin and atazanavir are substrates and inhibitors of CYP3A, and there is evidence of a bi-directional drug interaction (see Atazanavir under “Drugs That Affect Clarithromycin” in the table below) [see Pharmacokinetics (12.3)]. Saquinavir: Both clarithromycin and saquinavir are substrates and inhibitors of CYP3A and there is evidence of a bi-directional drug interaction (see Saquinavir under “Drugs That Affect Clarithromycin” in the table below) [see Pharmacokinetics (12.3)].

Ritonavir, Etravirine: (see Ritonavir and Etravirine under “Drugs That Affect Clarithromycin” in the table below) [see Pharmacokinetics (12.3)]. Maraviroc: Clarithromycin may result in increases in maraviroc exposures by inhibition of CYP3A metabolism. See Selzentry ® prescribing information for dose recommendation when given with strong CYP3A inhibitors such as clarithromycin.

Boceprevir: Both clarithromycin and boceprevir are substrates and inhibitors of CYP3A, potentially leading to a bi-directional drug interaction when co-administered. No dose adjustments are necessary for patients with normal renal function (see Victrelis ® prescribing information). Zidovudine: Simultaneous oral administration of clarithromycin immediate-release tablets and zidovudine to HIV-infected adult patients may result in decreased steady-state zidovudine concentrations.

Administration of clarithromycin and zidovudine should be separated by at least two hours [see Pharmacokinetics (12.3)]. Calcium Channel Blockers: Verapamil Amlodipine Diltiazem Nifedipine Use With Caution Verapamil: Hypotension, bradyarrhythmias, and lactic acidosis have been observed in patients receiving concurrent verapamil, [see Warnings and Precautions (5.4)].

Amlodipine, Diltiazem: [See Warnings and Precautions (5.4)] Nifedipine: Nifedipine is a substrate for CYP3A. Clarithromycin and other macrolides are known to inhibit CYP3A. There is potential of CYP3A-mediated interaction between nifedipine and clarithromycin. Hypotension and peripheral edema were observed when clarithromycin was taken concomitantly with nifedipine [see Warnings and Precautions (5.4)].

Ergot Alkaloids: Ergotamine Dihydroergotamine Contraindicated Ergotamine, Dihydroergotamine: Postmarketing reports indicate that coadministration of clarithromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system [see Contraindications (4.6)]. Gastroprokinetic Agents: Cisapride Contraindicated Cisapride: [See Contraindications (4.2)] Lipid-lowering agents: Lomitapide Lovastatin Simvastatin Atorvastatin Pravastatin Fluvastatin Contraindicated Use With Caution No Dose Adjustment Lomitapide, Lovastatin, Simvastatin: Clarithromycin may increase the exposure of these drugs by inhibition of CYP3A metabolism, thereby increasing the risk of toxicities from these drugs [see Contraindications (4.5) and Warnings and Precautions (5.4)] Atorvastatin, Pravastatin, Fluvastatin: [See Warnings and Precautions (5.4)] Hypoglycemic Agents: Nateglinide Pioglitazone Repaglinide Rosiglitazone Insulin Use With Caution Nateglinide, Pioglitazone, Repaglinide, Rosiglitazone: [See Warnings and Precautions (5.4) and Adverse Reactions (6.2)] Insulin: [See Warnings and Precautions (5.4) and Adverse Reactions (6.2)] Immunosuppressants: Cyclosporine Tacrolimus Use With Caution Cyclosporine: There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with cyclosporine.

Tacrolimus: There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with tacrolimus. Phosphodiesterase inhibitors: Sildenafil Tadalafil Vardenafil Use With Caution Sildenafil, Tadalafil, Vardenafil: Each of these phosphodiesterase inhibitors is primarily metabolized by CYP3A, and CYP3A will be inhibited by concomitant administration of clarithromycin.

Co-administration of clarithromycin with sildenafil, tadalafil, or vardenafil will result in increased exposure of these phosphodiesterase inhibitors. Co-administration of these phosphodiesterase inhibitors with clarithromycin is not recommended. Increased systemic exposure of these drugs may occur with clarithromycin; reduction of dosage for phosphodiesterase inhibitors should be considered (see their respective prescribing information).

Proton Pump Inhibitors: Omeprazole No Dose Adjustment Omeprazole: The mean 24-hour gastric pH value was 5.2 when omeprazole was administered alone and 5.7 when coadministered with clarithromycin as a result of increased omeprazole exposures [see Pharmacokinetics (12.3)] (see also Omeprazole under “Drugs That Affect Clarithromycin” in the table below). Xanthine Derivatives: Theophylline Use With Caution Theophylline: Clarithromycin use in patients who are receiving theophylline may be associated with an increase of serum theophylline concentrations [see Pharmacokinetics (12.3)].

Monitoring of serum theophylline concentrations should be considered for patients receiving high doses of theophylline or with baseline concentrations in the upper therapeutic range. Triazolobenzodiazepines and Other Related Benzodiazepines: Midazolam Alprazolam Triazolam Temazepam Nitrazepam Lorazepam Use With Caution No Dose Adjustment Midazolam: When oral midazolam is co-administered with clarithromycin, dose adjustments may be necessary and possible prolongation and intensity of effect should be anticipated [see Warnings and Precautions (5.4) and Pharmacokinetics (12.3)].

Triazolam, Alprazolam: Caution and appropriate dose adjustments should be considered when triazolam or alprazolam is co-administered with clarithromycin. There have been postmarketing reports of drug interactions and central nervous system (CNS) effects (e.g., somnolence and confusion) with the concomitant use of clarithromycin and triazolam.

Monitoring the patient for increased CNS pharmacological effects is suggested. In postmarketing experience, erythromycin has been reported to decrease the clearance of triazolam and midazolam, and thus, may increase the pharmacologic effect of these benzodiazepines. Temazepam, Nitrazepam, Lorazepam: For benzodiazepines which are not metabolized by CYP3A (e.g., temazepam, nitrazepam, lorazepam), a clinically important interaction with clarithromycin is unlikely.

Cytochrome P450 Inducers: Rifabutin Use With Caution Rifabutin: Concomitant administration of rifabutin and clarithromycin resulted in an increase in rifabutin, and decrease in clarithromycin serum levels together with an increased risk of uveitis (see Rifabutin under “Drugs That Affect Clarithromycin” in the table below). Other Drugs Metabolized by CYP3A: Alfentanil Bromocriptine Cilostazol Methylprednisole Vinblastine Phenobarbital St.

John’s Wort Use With Caution There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with alfentanil, methylprednisolone, cilostazol, bromocriptine, vinblastine, phenobarbital, and St. John’s Wort. Other Drugs Metabolized by CYP450 Isoforms Other than CYP3A: Hexobarbital Phenytoin Valproate Use With Caution There have been postmarketing reports of interactions of clarithromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate.

Drugs that Affect Clarithromycin Drug(s) that Affect the Pharmacokinetics of Clarithromycin Recommendation Comments Antifungals: Itraconazole Use With Caution Itraconazole: Itraconazole may increase the plasma concentrations of clarithromycin. Patients taking itraconazole and clarithromycin concomitantly should be monitored closely for signs or symptoms of increased or prolonged adverse reactions (see also Itraconazole under “Drugs That Are Affected By Clarithromycin” in the table above).

Antivirals: Atazanavir Ritonavir (in patients with decreased renal function) Saquinavir (in patients with decreased renal function) Etravirine Saquinavir (in patients with normal renal function) Ritonavir (in patients with normal renal function) Use With Caution No Dose Adjustment Atazanavir: When clarithromycin is co-administered with atazanavir, the dose of clarithromycin should be decreased by 50% [see Clinical Pharmacology (12.3)]. Since concentrations of 14-OH clarithromycin are significantly reduced when clarithromycin is co-administered with atazanavir, alternative antibacterial therapy should be considered for indications other than infections due to Mycobacterium avium complex.

Doses of clarithromycin greater than 1000 mg per day should not be co-administered with protease inhibitors. Ritonavir: Since concentrations of 14-OH clarithromycin are significantly reduced when clarithromycin is co-administered with ritonavir, alternative antibacterial therapy should be considered for indications other than infections due to Mycobacterium avium [see Pharmacokinetics (12.3)].

Doses of clarithromycin greater than 1000 mg per day should not be co-administered with protease inhibitors. Saquinavir: When saquinavir is co-administered with ritonavir, consideration should be given to the potential effects of ritonavir on clarithromycin (refer to ritonavir above) [see Pharmacokinetics (12.3)]. Etravirine: Clarithromycin exposure was decreased by etravirine; however, concentrations of the active metabolite, 14-OH-clarithromycin, were increased.

Because 14-OH-clarithromycin has reduced activity against Mycobacterium avium complex (MAC), overall activity against this pathogen may be altered; therefore alternatives to clarithromycin should be considered for the treatment of MAC. Proton Pump Inhibitors: Omeprazole Use With Caution Omeprazole: Clarithromycin concentrations in the gastric tissue and mucus were also increased by concomitant administration of omeprazole [see Pharmacokinetics (12.3)].

Miscellaneous Cytochrome P450 Inducers: Efavirenz Nevirapine Rifampicin Rifabutin Rifapentine Use With Caution Inducers of CYP3A enzymes, such as efavirenz, nevirapine, rifampicin, rifabutin, and rifapentine will increase the metabolism of clarithromycin, thus decreasing plasma concentrations of clarithromycin, while increasing those of 14-OH-clarithromycin. Since the microbiological activities of clarithromycin and 14-OH-clarithromycin are different for different bacteria, the intended therapeutic effect could be impaired during concomitant administration of clarithromycin and enzyme inducers.

Alternative antibacterial treatment should be considered when treating patients receiving inducers of CYP3A. There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with rifabutin (see Rifabutin under “Drugs That Are Affected By Clarithromycin” in the table above). Co-administration of clarithromycin can alter the concentrations of other drugs.

The potential for drug-drug interactions must be considered prior to and during therapy. (4, 5.2, 5.4, 7)

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

7 DRUG INTERACTIONS Co-administration of clarithromycin is known to inhibit CYP3A, and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug.

Clarithromycin should be used with caution in patients receiving treatment with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g., carbamazepine) and/or the substrate is extensively metabolized by this enzyme.

Adjust dosage when appropriate and monitor serum concentrations of drugs primarily metabolized by CYP3A closely in patients concurrently receiving clarithromycin.

There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with disopyramide and quinidine.

Digoxin : Digoxin is a substrate for P-glycoprotein (Pgp) and clarithromycin is known to inhibit Pgp.

There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with carbamazepine.

Antifungals: Itraconazole Fluconazole Use With Caution No Dose Adjustment Itraconazole: Both clarithromycin and itraconazole are substrates and inhibitors of CYP3A, potentially leading to a bi-directional drug interaction when administered concomitantly (see also Itraconazole under “Drugs That Affect Clarithromycin” in the table below).

Fluconazole: [see Pharmacokinetics (12.3) ] Anti-Gout Agents: Colchicine (in patients with renal or hepatic impairment) Colchicine (in patients with normal renal and hepatic function) Contraindicated Use With Caution Colchicine : Colchicine is a substrate for both CYP3A and the efflux transporter, P-glycoprotein (Pgp).

Adverse reactions

Common

  • Abdominal pain, diarrhea, nausea, vomiting
  • Taste disturbance

Serious

  • Severe hypersensitivity
  • QT prolongation and torsades de pointes
  • Hepatotoxicity
  • Drug-interaction toxicity (colchicine, statins, calcium channel blockers)
  • Clostridioides difficile-associated diarrhea
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label
  • The following serious adverse reactions are described below and elsewhere in the labeling: • Acute Hypersensitivity Reactions [see Warnings and Precautions (5.1)] • QT Prolongation [see Warnings and Precautions (5.2)] • Hepatotoxicity [see Warnings and Precautions (5.3)] • Serious Adverse Reactions Due to Concomitant Use with Other Drugs [see Warnings and Precautions (5.4)] • Clostridium difficile Associated Diarrhea [see Warnings and Precautions (5.6)] • Exacerbation of Myasthenia Gravis [see Warnings and Precautions (5.8)] Most frequent adverse reactions for both adult and pediatric populations in clinical trials: abdominal pain, diarrhea, nausea, vomiting, dysgeusia (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Based on pooled data across all indications, the most frequent adverse reactions for both adult and pediatric populations observed in clinical trials are abdominal pain, diarrhea, nausea, vomiting and dysgeusia.

Also reported were dyspepsia, liver function test abnormal, anaphylactic reaction, candidiasis, headache, insomnia, and rash. The subsequent subsections list the most common adverse reactions for prophylaxis and treatment of mycobacterial infections and duodenal ulcer associated with H. pylori infection. In general, these profiles are consistent with the pooled data described above.

Prophylaxis of Mycobacterial Infections In AIDS patients treated with clarithromycin over long periods of time for prophylaxis against M. avium, it was often difficult to distinguish adverse reactions possibly associated with clarithromycin administration from underlying HIV disease or intercurrent illness. Median duration of treatment was 10.6 months for the clarithromycin group and 8.2 months for the placebo group.

Table 4. Incidence Rates (%) of Selected Adverse Reactions a in Immunocompromised Adult Patients Receiving Prophylaxis Against M. avium Complex Body System b Adverse Reaction Clarithromycin (n=339) % Placebo (n=339) % Body as a Whole Abdominal pain 5% 4% Headache 3% 1% Digestive Diarrhea 8% 4% Dyspepsia 4% 3% Flatulence 2% 1% Nausea 11% 7% Vomiting 6% 3% Skin & Appendages Rash 3% 4% Special Senses Taste Perversion 8% c 0.3% a Includes those events possibly or probably related to study drug and excludes concurrent conditions b 2% or greater Adverse Reaction Incidence Rates for either treatment group c Significant higher incidence compared to the placebo-treated group Discontinuation due to adverse reactions occurred in 18% of patients receiving clarithromycin compared to 17% of patients receiving placebo in this trial.

Primary reasons for discontinuation in clarithromycin treated patients include headache, nausea, vomiting, depression, and taste perversion. Changes in Laboratory Values Selected laboratory adverse experiences that were reported during therapy in greater than 2 % of adult patients treated with clarithromycin in a randomized double-blind clinical trial involving 682 patients are presented in Table 5.

In immunocompromised patients receiving prophylaxis against M. avium, evaluations of laboratory values were made by analyzing those values outside the seriously abnormal value (i.e., the extreme high or low limit) for the specified test. Table 5. Percentage of Patients a Exceeding Extreme Laboratory Values in Patients Receiving Prophylaxis Against M. avium Complex Clarithromycin 500 mg twice a day Placebo WBC Count <1 x 10 9 /L 2/103 (4%) 0/95 SGOT >5 x ULN b 7/196 (4%) 5/208 (2%) SGPT >5 x ULN b 6/217 (3%) 4/232 (2%) a Includes only patients with baseline values within the normal range or borderline high (hematology variables) and within normal range or borderline low (chemistry variables) b ULN= Upper Limit of Normal Treatment of Mycobacterial Infections The adverse reaction profiles for both the 500 mg and 1000 mg twice a day dose regimens were similar.

In AIDS patients and other immunocompromised patients treated with the higher doses of clarithromycin over long periods of time for mycobacterial infections, it was often difficult to distinguish adverse reactions possibly associated with clarithromycin administration from underlying signs of HIV disease or intercurrent illness. The following analysis summarizes experience during the first 12 weeks of therapy with clarithromycin.

Data are reported separately for trial 1 (randomized, double-blind) and trial 2 (open-labeled, compassionate use) and also combined. Adverse reactions were reported less frequently in trial 2, which may be due in part to differences in monitoring between the two studies. In adult patients receiving clarithromycin 500 mg twice a day, the most frequently reported adverse reactions, considered possibly or possibly related to study drug, with an incidence of 5% or greater, are listed below (Table 6).

Approximately 8% of the patients who received 500 mg twice a day and 12% of the patients who received 1000 mg twice a day discontinued therapy due to drug related adverse reactions during the first 12 weeks of therapy; adverse reactions leading to discontinuation in at least 2 patients included nausea, vomiting, abdominal pain, diarrhea, rash, and asthenia. Table 6.

Selected Treatment-Related a Adverse Reaction Incidence Rates (%) in Immunocompromised Adult Patients During the First 12 Weeks of Therapy with 500 mg Twice a Day Clarithromycin Dose Adverse Reaction Trial 1 (n=53) Trial 2 (n=255) Combined (n=308) Abdominal Pain 8 2 3 Diarrhea 9 2 3 Flatulence 8 0 1 Headache 8 0 2 Nausea 28 9 12 Rash 9 2 3 Taste Perversion 19 0 4 Vomiting 25 4 8 a Includes those events possibly or probably related to study drug and excludes concurrent conditions A limited number of pediatric AIDS patients have been treated with clarithromycin suspension for mycobacterial infections. The most frequently reported adverse reactions excluding those due to the patient’s concurrent conditions were consistent with those observed in adult patients.

Changes in Laboratory Values In the first 12 weeks of starting on clarithromycin 500 mg twice a day, 3% of patients has SGOT increases and 2% of patients has SGPT increases > 5 times the upper limit of normal in trial 2 (469 enrolled adult patients) while trial 1 (154 enrolled patients) had no elevation of transaminases. This includes only patients with baseline values within the normal range or borderline low.

Duodenal ulcer associated with H. pylori Infection In clinical trials using combination therapy with clarithromycin plus omeprazole and amoxicillin, no adverse reactions specific to the combination of these drugs have been observed. Adverse reactions that have occurred have been limited to those that have been previously reported with clarithromycin, omeprazole or amoxicillin.

The adverse reaction profiles are shown below (Table 7) for four randomized double-blind clinical trials in which patients received the combination of clarithromycin 500 mg three times a day, and omeprazole 40 mg daily for 14 days, followed by omeprazole 20 mg once a day, (three studies) or 40 mg once a day (one study) for an additional 14 days. Of the 346 patients who received the combination, 3.5% of patients discontinued drug due to adverse reactions.

Table 7. Adverse Reactions with an Incidence of 3% or Greater Adverse Reaction Clarithromycin + Omeprazole (n=346) % of Patients Omeprazole (n=355) % of Patients Clarithromycin (n=166) % of Patients a Taste Perversion 15 1 16 Nausea 5 1 3 Headache 5 6 9 Diarrhea 4 3 7 Vomiting 4 <1 1 Abdominal Pain 3 2 1 Infection 3 4 2 a Only two of four studies Changes in Laboratory Values Changes in laboratory values with possible clinical significance in patients taking clarithromycin and omeprazole in four randomized double-blind trials in 945 patients are as follows: Hepatic: elevated direct bilirubin <1%; GGT <1%; SGOT (AST) <1%; SGPT (ALT) <1%, Renal: elevated serum creatinine <1%.

Less Frequent Adverse Reactions Observed During Clinical Trials of Clarithromycin Based on pooled data across all indications, the following adverse reactions were observed in clinical trials with clarithromycin at a rate less than 1%: Blood and Lymphatic System Disorders: Leukopenia, neutropenia, thrombocythemia, eosinophilia Cardiac Disorders: Electrocardiogram QT prolonged, cardiac arrest, atrial fibrillation, extrasystoles, palpitations Ear and Labyrinth Disorders: Vertigo, tinnitus, hearing impaired Gastrointestinal Disorders: Stomatitis, glossitis, esophagitis, gastrooesophageal reflux disease, gastritis, proctalgia, abdominal distension, constipation, dry mouth, eructation, flatulence General Disorders and Administration Site Conditions: Malaise, pyrexia, asthenia, chest pain, chills, fatigue Hepatobiliary Disorders: Cholestasis, hepatitis Immune System Disorders: Hypersensitivity Infections and Infestations: Cellulitis, gastroenteritis, infection, vaginal infection Investigations: Blood bilirubin increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, albumin globulin ratio abnormal Metabolism and Nutrition Disorders: Anorexia, decreased appetite Musculoskeletal and Connective Tissue Disorders: Myalgia, muscle spasms, nuchal rigidity Nervous System Disorders: Dizziness, tremor, loss of consciousness, dyskinesia, somnolence Psychiatric Disorders: Anxiety, nervousness Renal and Urinary Disorders: Blood creatinine increased, blood urea increased Respiratory, Thoracic and Mediastinal Disorders: Asthma, epistaxis, pulmonary embolism Skin and Subcutaneous Tissue Disorders: Urticaria, dermatitis bullous, pruritus, hyperhidrosis, rash maculo-papular Gastrointestinal Adverse Reactions In the acute exacerbation of chronic bronchitis and acute maxillary sinusitis studies overall gastrointestinal adverse reactions were reported by a similar proportion of patients taking either clarithromycin tablets or clarithromycin extended-release tablets; however, patients taking clarithromycin extended-release tablets reported significantly less severe gastrointestinal symptoms compared to patients taking clarithromycin tablets. In addition, patients taking clarithromycin extended-release tablets had significantly fewer premature discontinuations for drug-related gastrointestinal or abnormal taste adverse reactions compared to clarithromycin tablets.

All-Cause Mortality in Patients with Coronary Artery Disease 1 to 10 Years Following Clarithromycin Exposure In one clinical trial evaluating treatment with clarithromycin on outcomes in patients with coronary artery disease, an increase in risk of all-cause mortality was observed in patients randomized to clarithromycin. Clarithromycin for treatment of coronary artery disease is not an approved indication.

Patients were treated with clarithromycin or placebo for 14 days and observed for primary outcome events (e.g., all-cause mortality or non-fatal cardiac events) for several years. 1 A numerically higher number of primary outcome events in patients randomized to receive clarithromycin was observed with a hazard ratio of 1.06 (95% confidence interval 0.98 to 1.14). However, at follow-up 10 years post-treatment, there were 866 (40%) deaths in the clarithromycin group and 815 (37%) deaths in the placebo group that represented a hazard ratio for all-cause mortality of 1.10 (95% confidence interval 1.00 to 1.21).

The difference in the number of deaths emerged after one year or more after the end of treatment. The cause of the difference in all-cause mortality has not been established. Other epidemiologic studies evaluating this risk have shown variable results [see Warnings and Precautions (5.5)].

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of clarithromycin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Blood and Lymphatic System: Thrombocytopenia, agranulocytosis Cardiac: Ventricular arrhythmia, ventricular tachycardia, torsades de pointes Ear and Labyrinth: Deafness was reported chiefly in elderly women and was usually reversible. Gastrointestinal: Pancreatitis acute, tongue discoloration, tooth discoloration was reported and was usually reversible with professional cleaning upon discontinuation of the drug.

There have been reports of clarithromycin extended-release tablets in the stool, many of which have occurred in patients with anatomic (including ileostomy or colostomy) or functional gastrointestinal disorders with shortened GI transit times. In several reports, tablet residues have occurred in the context of diarrhea.

It is recommended that patients who experience tablet residue in the stool and no improvement in their condition should be switched to a different clarithromycin formulation (e.g., suspension) or another antibacterial drug. Hepatobiliary: Hepatic failure, jaundice hepatocellular. Adverse reactions related to hepatic dysfunction have been reported with clarithromycin [see Warnings and Precautions (5.2)].

Infections and Infestations: Pseudomembranous colitis [see Warnings and Precautions (5.6)] Immune System: Anaphylactic reactions, angioedema Investigations: Prothrombin time prolonged, white blood cell count decreased, international normalized ratio increased. Abnormal urine color has been reported, associated with hepatic failure.

Metabolism and Nutrition: Hypoglycemia has been reported in patients taking oral hypoglycemic agents or insulin. Musculoskeletal and Connective Tissue: Myopathy rhabdomyolysis was reported and in some of the reports, clarithromycin was administered concomitantly with statins, fibrates, colchicine or allopurinol [see Contraindications (4.5) and Warnings and Precautions (5.4)].

Nervous System: Parosmia, anosmia, ageusia, paresthesia and convulsions Psychiatric: Abnormal behavior, confusional state, depersonalization, disorientation, hallucination, depression, manic behavior, abnormal dream, psychotic disorder. These disorders usually resolve upon discontinuation of the drug. Renal and Urinary: Nephritis interstitial, renal failure Skin and Subcutaneous Tissue: Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS), Henoch-Schonlein purpura, acne, acute generalized exanthematous pustulosis Vascular: Hemorrhage

Adverse reaction frequency tables (US label) US FDA label
Body System b Adverse Reaction Clarithromycin (n=339) % Placebo (n=339) %
Body as a Whole
Abdominal pain 5% 4%
Headache 3% 1%
Digestive
Diarrhea 8% 4%
Dyspepsia 4% 3%
Flatulence 2% 1%
Nausea 11% 7%
Vomiting 6% 3%
Skin & Appendages
Rash 3% 4%
Special Senses
Taste Perversion 8% c 0.3%
aIncludes those events possibly or probably related to study drug and excludes concurrent conditions b2% or greater Adverse Reaction Incidence Rates for either treatment group cSignificant higher incidence compared to the placebo-treated group
Clarithromycin 500 mg twice a day Placebo
WBC Count <1 x 10 9/L 2/103 (4%) 0/95
SGOT >5 x ULN b 7/196 (4%) 5/208 (2%)
SGPT >5 x ULN b 6/217 (3%) 4/232 (2%)
aIncludes only patients with baseline values within the normal range or borderline high (hematology variables) and within normal range or borderline low (chemistry variables) bULN= Upper Limit of Normal
Adverse Reaction Trial 1 (n=53) Trial 2 (n=255) Combined (n=308)
Abdominal Pain 8 2 3
Diarrhea 9 2 3
Flatulence 8 0 1
Headache 8 0 2
Nausea 28 9 12
Rash 9 2 3
Taste Perversion 19 0 4
Vomiting 25 4 8
aIncludes those events possibly or probably related to study drug and excludes concurrent conditions
Adverse Reaction Clarithromycin + Omeprazole (n=346) % of Patients Omeprazole (n=355) % of Patients Clarithromycin (n=166) % of Patients a
Taste Perversion 15 1 16
Nausea 5 1 3
Headache 5 6 9
Diarrhea 4 3 7
Vomiting 4 <1 1
Abdominal Pain 3 2 1
Infection 3 4 2
aOnly two of four studies

Monitoring parameters

  • CrCl for dose; QT interval and potassium/magnesium; liver tests; levels of CYP3A substrates (tacrolimus, cyclosporine, carbamazepine) and digoxin; blood pressure and kidney function with CYP3A-metabolized calcium channel blockers (label). Kidney
  • CrCl for dose
  • QT and electrolytes when at risk
  • Levels of interacting drugs
renalcarematters.com, reviewed

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Based on findings from animal studies, clarithromycin is not recommended for use in pregnant women except in clinical circumstances where no alternative therapy is appropriate. If pregnancy occurs while taking clarithromycin, the patient should be apprised of the potential hazard to the fetus [see Warnings and Precautions (5.7)].

Limited data from a small number of published human studies with clarithromycin use during pregnancy are insufficient to inform drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies, administration of oral clarithromycin to pregnant mice, rats, rabbits, and monkeys during the period of organogenesis produced malformations in rats (cardiovascular anomalies) and mice (cleft palate) at clinically relevant doses based on body surface area comparison.

Fetal effects in mice, rats, and monkeys (e.g., reduced fetal survival, body weight, body weight gain) and implantation losses in rabbits were generally considered to be secondary to maternal toxicity (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Animal reproduction studies were conducted in mice, rats, rabbits, and monkeys with oral and intravenously administered clarithromycin.

In pregnant mice, clarithromycin was administered during organogenesis (gestation day [GD] 6 to 15) at oral doses of 15, 60, 250, 500, or 1000 mg/kg/day. Reduced body weight observed in dams at 1000 mg/kg/day (3 times the maximum recommended human dose [MRHD] based on body surface area comparison) resulted in reduced survival and body weight of the fetuses.

At ≥ 500 mg/kg/day, increases in the incidence of postimplantation loss and cleft palate in the fetuses were observed. No adverse developmental effects were observed in mice at ≤ 250 mg/kg/day (≤ 1 times MRHD based on body surface area comparison). In pregnant Sprague Dawley rats, clarithromycin was administered during organogenesis (GD 6 to 15) at oral doses of 15, 50, or 150 mg/kg/day.

Reductions in body weight and food consumption was observed in dams at 150 mg/kg/day. Increased resorptions and reduced body weight of the fetuses at this dose were considered secondary to maternal toxicity. Additionally, at 150 mg/kg/day (1 times MRHD based on body surface area comparison), a low incidence of cardiovascular anomalies (complete situs inversus, undivided truncus, IV septal defect) was observed in the fetuses.

Clarithromycin did not cause adverse developmental effects in rats at 50 mg/kg/day (0.3 times MRHD based on body surface area comparison). Intravenous dosing of clarithromycin during organogenesis in rats (GD 6 to 15) at 15, 50, or 160 mg/kg/day was associated with maternal toxicity (reduced body weight, body-weight gain, and food consumption) at 160 mg/kg/day but no evidence of adverse developmental effects at any dose (≤ 1 times MRHD based on body surface area comparison).

In pregnant Wistar rat, clarithromycin was administered during organogenesis (GD 7 to 17) at oral doses of 10, 40, or 160 mg/kg/day. Reduced body weight and food consumption were observed in dams at 160 mg/kg/day but there was no evidence of adverse developmental effects at any dose (≤ 1 times MRHD based on body surface area comparison).

In pregnant rabbits, clarithromycin administered during organogenesis (GD 6 to 18) at oral doses of 10, 35, or 125 mg/kg/day resulted in reduced maternal food consumption and decreased body weight at the highest dose, with no evidence of any adverse developmental effects at any dose (≤ 2 times MRHD based on body surface area comparison). Intravenously administered clarithromycin to pregnant rabbits during organogenesis (GD 6 to 18) in rabbits at 20, 40, 80, or 160 mg/kg/day (≥ 0.3 times MRHD based on body surface area comparison) resulted in maternal toxicity and implantation losses at all doses.

In pregnant monkeys, clarithromycin was administered (GD 20 to 50) at oral doses of 35 or 70 mg/kg/day. Dose-dependent emesis, poor appetite, fecal changes, and reduced body weight were observed in dams at all doses (≥ 0.5 times MRHD based on body surface area comparison). Growth retardation in 1 fetus at 70 mg/kg/day was considered secondary to maternal toxicity.

There was no evidence of primary drug related adverse developmental effects at any dose tested. In a reproductive toxicology study in rats administered oral clarithromycin late in gestation through lactation (GD 17 to post-natal day 21) at doses of 10, 40, or 160 mg/kg/day (≤ 1 times MRHD based on body surface area comparison), reductions in maternal body weight and food consumption were observed at 160 mg/kg/day.

Reduced body-weight gain observed in offspring at 160 mg/kg/day was considered secondary to maternal toxicity. No adverse developmental effects were observed with clarithromycin at any dose tested.

Breastfeeding considerations

Lactation (US label) US FDA label

8.3 Females and Males of Reproductive Potential Males Administration of clarithromycin resulted in testicular atrophy in rats, dogs and monkeys [see Nonclinical Toxicology (13.1)].

Mechanism of action

12.1 Mechanism of Action Clarithromycin is a macrolide antimicrobial drug [see Microbiology (12.4)].

US FDA label

Pharmacokinetics

Key PK parameters

BioavailabilityAbout 50%
Half-life3 to 4 hours (250 mg every 12 hours); 5 to 7 hours (500 mg)
Metabolism (CYP, transporters)Hepatic (CYP3A)
Active metabolites14-OH clarithromycin (half-life 5 to 9 hours)
Renal excretion kidneyAbout 20% (250 mg) to 30% (500 mg) unchanged in urine
Dialyzability kidneyNo (label)
renalcarematters.com, reviewed
Half-life and elimination (verbatim, US label)

The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.

With a 250 mg every 12 hours dosing, the principal metabolite, 14-OH clarithromycin, attains a peak steady-state concentration of about 0.6 mcg/mL and has an elimination half-life of 5 hours to 6 hours.

With a 500 mg every 8 hours to 12 hours dosing, the peak steady-state concentration of 14-OH clarithromycin is slightly higher (up to 1 mcg/mL), and its elimination half-life is about 7 hours to 9 hours.

After a 250 mg tablet every 12 hours, approximately 20% of the dose is excreted in the urine as clarithromycin, while after a 500 mg tablet every 12 hours, the urinary excretion of clarithromycin is somewhat greater, approximately 30%.

In comparison, after an oral dose of 250 mg (125 mg/5 mL) suspension every 12 hours, approximately 40% is excreted in urine as clarithromycin.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Absorption The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%. For a single 500 mg dose of clarithromycin, food slightly delays the onset of clarithromycin absorption, increasing the peak time from approximately 2 to 2.5 hours. Food also increases the clarithromycin peak plasma concentration by about 24%, but does not affect the extent of clarithromycin bioavailability.

Food does not affect the onset of formation of the active metabolite, 14-OH clarithromycin or its peak plasma concentration but does slightly decrease the extent of metabolite formation, indicated by an 11% decrease in area under the plasma concentration-time curve (AUC). Therefore, clarithromycin tablets may be given without regard to food.

In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing. Distribution Clarithromycin and the 14-OH clarithromycin metabolite distribute readily into body tissues and fluids. There are no data available on cerebrospinal fluid penetration. Because of high intracellular concentrations, tissue concentrations are higher than serum concentrations.

Examples of tissue and serum concentrations are presented below. Table 9. Tissue and Serum Concentrations of Clarithromycin CONCENTRATION (after 250 mg every 12 hours) Tissue Type Tissue (mcg/g) Serum (mcg/mL) Tonsil 1.6 0.8 Lung 8.8 1.7 Metabolism and Elimination Steady-state peak plasma clarithromycin concentrations were attained within 3 days and were approximately 1 mcg/mL to 2 mcg/mL with a 250 mg dose administered every 12 hours and 3 mcg/mL to 4 mcg/mL with a 500 mg dose administered every 8 hours to 12 hours.

The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours. The nonlinearity of clarithromycin pharmacokinetics is slight at the recommended doses of 250 mg and 500 mg administered every 8 hours to 12 hours.

With a 250 mg every 12 hours dosing, the principal metabolite, 14-OH clarithromycin, attains a peak steady-state concentration of about 0.6 mcg/mL and has an elimination half-life of 5 hours to 6 hours. With a 500 mg every 8 hours to 12 hours dosing, the peak steady-state concentration of 14-OH clarithromycin is slightly higher (up to 1 mcg/mL), and its elimination half-life is about 7 hours to 9 hours.

With any of these dosing regimens, the steady-state concentration of this metabolite is generally attained within 3 days to 4 days. After a 250 mg tablet every 12 hours, approximately 20% of the dose is excreted in the urine as clarithromycin, while after a 500 mg tablet every 12 hours, the urinary excretion of clarithromycin is somewhat greater, approximately 30%.

In comparison, after an oral dose of 250 mg (125 mg/5 mL) suspension every 12 hours, approximately 40% is excreted in urine as clarithromycin. The renal clearance of clarithromycin is, however, relatively independent of the dose size and approximates the normal glomerular filtration rate. The major metabolite found in urine is 14-OH clarithromycin, which accounts for an additional 10% to 15% of the dose with either a 250 mg or a 500 mg tablet administered every 12 hours.

Specific Populations for Clarithromycin Tablets HIV Infection Steady-state concentrations of clarithromycin and 14-OH clarithromycin observed following administration of 500 mg doses of clarithromycin every 12 hours to adult patients with HIV infection were similar to those observed in healthy volunteers. In adult HIV-infected patients taking 500 mg or 1000 mg doses of clarithromycin every 12 hours, steady-state clarithromycin C max values ranged from 2 mcg/mL to 4 mcg/mL and 5 mcg/mL to 10 mcg/mL, respectively.

Hepatic Impairment The steady-state concentrations of clarithromycin in subjects with impaired hepatic function did not differ from those in normal subjects; however, the 14-OH clarithromycin concentrations were lower in the hepatically impaired subjects. The decreased formation of 14-OH clarithromycin was at least partially offset by an increase in renal clearance of clarithromycin in the subjects with impaired hepatic function when compared to healthy subjects.

Renal Impairment The pharmacokinetics of clarithromycin was also altered in subjects with impaired renal function [see Use in Specific Populations (8.6) and Dosage and Administration (2.6)]. Drug Interactions Fluconazole Following administration of fluconazole 200 mg daily and clarithromycin 500 mg twice daily to 21 healthy volunteers, the steady-state clarithromycin C min and AUC increased 33% and 18%, respectively.

Clarithromycin exposures were increased and steady-state concentrations of 14-OH clarithromycin were not significantly affected by concomitant administration of fluconazole. Colchicine When a single dose of colchicine 0.6 mg was administered with clarithromycin 250 mg BID for 7 days, the colchicine C max increased 197% and the AUC 0-∞ increased 239% compared to administration of colchicine alone.

Atazanavir Following administration of clarithromycin (500 mg twice daily) with atazanavir (400 mg once daily), the clarithromycin AUC increased 94%, the 14-OH clarithromycin AUC decreased 70% and the atazanavir AUC increased 28%. Ritonavir Concomitant administration of clarithromycin and ritonavir (n = 22) resulted in a 77% increase in clarithromycin AUC and a 100% decrease in the AUC of 14-OH clarithromycin.

Saquinavir Following administration of clarithromycin (500 mg bid) and saquinavir (soft gelatin capsules, 1200 mg tid) to 12 healthy volunteers, the steady-state saquinavir AUC and C max increased 177% and 187% respectively compared to administration of saquinavir alone. Clarithromycin AUC and C max increased 45% and 39% respectively, whereas the 14–OH clarithromycin AUC and C max decreased 24% and 34% respectively, compared to administration with clarithromycin alone.

Didanosine Simultaneous administration of clarithromycin tablets and didanosine to 12 HIV-infected adult patients resulted in no statistically significant change in didanosine pharmacokinetics. Zidovudine Following administration of clarithromycin 500 mg tablets twice daily with zidovudine 100 mg every 4 hours, the steady-state zidovudine AUC decreased 12% compared to administration of zidovudine alone (n=4).

Individual values ranged from a decrease of 34% to an increase of 14%. When clarithromycin tablets were administered two to four hours prior to zidovudine, the steady-state zidovudine C max increased 100% whereas the AUC was unaffected (n=24). Omeprazole Clarithromycin 500 mg every 8 hours was given in combination with omeprazole 40 mg daily to healthy adult subjects.

The steady-state plasma concentrations of omeprazole were increased (C max, AUC 0-24, and t ½ increases of 30%, 89%, and 34%, respectively), by the concomitant administration of clarithromycin. The plasma levels of clarithromycin and 14–OH clarithromycin were increased by the concomitant administration of omeprazole. For clarithromycin, the mean C max was 10% greater, the mean C min was 27% greater, and the mean AUC 0-8 was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone.

Similar results were seen for 14–OH clarithromycin, the mean C max was 45% greater, the mean C min was 57% greater, and the mean AUC 0-8 was 45% greater. Clarithromycin concentrations in the gastric tissue and mucus were also increased by concomitant administration of omeprazole. Clarithromycin Tissue Concentrations 2 hours after Dose (mcg/mL)/(mcg/g) Treatment N antrum fundus N Mucus Clarithromycin 5 10.48 ± 2.01 20.81 ± 7.64 4 4.15 ± 7.74 Clarithromycin + Omeprazole 5 19.96 ± 4.71 24.25 ± 6.37 4 39.29 ± 32.79 Theophylline In two studies in which theophylline was administered with clarithromycin (a theophylline sustained-release formulation was dosed at either 6.5 mg/kg or 12 mg/kg together with 250 or 500 mg q12h clarithromycin), the steady-state levels of C max, C min, and the area under the serum concentration time curve (AUC) of theophylline increased about 20%.

Midazolam When a single dose of midazolam was co-administered with clarithromycin tablets (500 mg twice daily for 7 days), midazolam AUC increased 174% after intravenous administration of midazolam and 600% after oral administration. For information about other drugs indicated in combination with clarithromycin, refer to their full prescribing information, CLINICAL PHARMACOLOGY section.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Clarithromycin 125 mg/5 mL, 50 mL Suspension₱90.00–₱293.50Reference ₱144.00per unitDPRI procurement range
Clarithromycin 500 mg Tablet₱7.00–₱19.20Reference ₱10.64per tabletDPRI procurement range
125 mg/5 mL granules/powder for suspension in 50 mL₱277.00per unitPhilHealth GAMOT fixed fee
250 mg (as base) tablet₱48.25per tabletPhilHealth GAMOT fixed fee
250 mg/5 mL granules/powder for suspension in 50 mL₱632.50per unitPhilHealth GAMOT fixed fee
500 mg (as base) tablet₱56.00per tabletPhilHealth GAMOT fixed fee

PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Clarithromycin
PNF listingOral: 250 mg and 500 mg base tablet
PNF listingOral: 125 mg/5 mL and 250 mg/5 mL granules/powder for suspension, 50 mL
PhilHealth GAMOTYes (listed since July 28, 2025)
PhilHealth YAKAP (formerly Konsulta)Yes

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Clarithromycin · Sportpharm LLC [US FDA-approved label, version 2, September 16, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d836ae7e-fdbf-4dcb-a90d-ede1dcbc3e67
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  5. PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  6. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
  7. Sportpharm LLC. (2026). Clarithromycin tablets, USP [Prescribing information; US FDA-approved label, ANDA065489, set ID d836ae7e-fdbf-4dcb-a90d-ede1dcbc3e67, version effective September 16, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d836ae7e-fdbf-4dcb-a90d-ede1dcbc3e67

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .